Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

Exhibit 10.1  

 
 

Development and License Agreement    
  

between

ImmunoGen, Inc.

128 Sidney Street

Cambridge, MA 02139

U.S.A. 

(hereinafter
called "ImmunoGen") 

and

Boehringer
Ingelheim International GmbH

Binger Strasse 173

55218 Ingelheim am Rhein

GERMANY 

(hereinafter
called "BI") 

having
an Effective Date of November 27, 2001 (the "Effective Date"). 

WITNESSETH:  

        WHEREAS, BI is a pharmaceutical company engaged in the research, development, manufacture and commercialisation of
pharmaceutical products and Controls certain patents and know-how related to the humanised monoclonal antibody BIWA4; and 

        WHEREAS, ImmunoGen Controls certain patents, and know-how related to ImmunoGen's maytansinoid DM1 technology, and it has the
right to grant certain rights and licenses thereunder as set forth herein; and 

        WHEREAS, BI desires to obtain a license from ImmunoGen to develop, manufacture, market and sell the Licensed Products in the Territory,
and ImmunoGen desires to grant such a license to BI, on the terms and conditions contained in this Agreement. 

        NOW THEREFORE, in consideration of the covenants and promises in this Agreement, ImmunoGen and BI agree as follows: 

1

   Table of Contents  

	1.	 	DEFINITIONS	 	3
	

2.	
 	

GRANT OF RIGHTS AND RESTRICTIONS	
 	

7
	

3.	
 	

PAYMENTS, REPORTS AND RECORDS	
 	

8
	

4.	
 	

DEVELOPMENT AND COMMERCIALISATION	
 	

12
	

5.	
 	

SUPPLY AND MANUFACTURING OBLIGATIONS	
 	

13
	

6.	
 	

PRODUCT INQUIRIES, COMPLAINTS AND ADVERSE EVENTS	
 	

14
	

7.	
 	

RIGHTS AND IMPROVEMENTS	
 	

15
	

8.	
 	

PATENTS AND TRADEMARKS	
 	

15
	

9.	
 	

INFRINGEMENT	
 	

17
	

10.	
 	

REPRESENTATIONS AND WARRANTIES	
 	

18
	

11.	
 	

INDEMNIFICATION	
 	

19
	

12.	
 	

CONFIDENTIALITY	
 	

20
	

13.	
 	

TERM AND TERMINATION	
 	

22
	

14.	
 	

EFFECTS OF TERMINATION	
 	

23
	

15.	
 	

MISCELLANEOUS	
 	

24
	

16.	
 	

SCHEDULES	
 	

25

2

  

	1.  	 	DEFINITIONS	 	 	 	 
	

1.1	
 	

"Adverse Event"	
 	

shall mean any untoward medical occurrence in a patient or subject who is administered a Licensed Product, whether or not considered related to the Licensed Product, including, without limitation, any undesirable sign (including abnormal laboratory
findings of clinical concern), symptom or disease temporally associated with the use of such Licensed Product.
	

1.2	
 	

"Affiliates"	
 	

shall mean any company or business entity which controls, is controlled by, or is under common control with, either ImmunoGen or BI. For purposes of this definition, "control" shall mean the possession, directly or indirectly or the power to direct
or cause the direction of the management and policies of an entity (other than a natural person), whether through the majority ownership of voting capital stock, by contract or otherwise.
	

1.3	
 	

"BI Materials"	
 	

shall mean any tangible chemical, biological or research materials, including without limitation, any assays or antibodies, whether or not patentable, used by BI or furnished by BI to ImmunoGen under this Agreement. BI Materials shall include,
without limitation, the BIWA4 antibody.
	

1.4	
 	

"BI Intellectual Property"	
 	

shall mean any Technology and Patent Rights Controlled by BI during the Term that are used by BI or provided by BI for use in the activities contemplated by this Agreement. BI Intellectual Property Patent Rights as of the Effective Date are described
on Schedule C.
	

1.5	
 	

"BIWI1"	
 	

shall mean any conjugate of "naked" BIWA4 with DM1.
	

1.6	
 	

"Commercially Reasonable Efforts"	
 	

shall mean the efforts and resources that BI would use for a compound owned by it or to which is has rights, which is of similar market potential at a similar stage in development as the applicable Licensed Product, taking into account the
competitiveness of the marketplace, the proprietary position of the Licensed Product, the profitability and the relative potential safety and efficacy of the Licensed Product, and other relevant factors including, without, limitation, technical,
legal, scientific or medical factors.
	

1.7	
 	

"Comparable Product"	
 	

shall mean any conjugate of DM1 that has the same Target Antigen as a Licensed Product.
	

1.8	
 	

"Competent Authorities"	
 	

shall mean the United States Food and Drug Administration (FDA), the European Commission and any foreign health authority charged with responsibility for regulating the approval to market a Licensed Product for the treatment of humans.
	

1.9	
 	

"Control"	
 	

shall mean, with respect to tangible or intangible property, including intellectual property or other matters, title to such property and/or possession of the ability to grant a license or sublicense to such property without violating any agreement
with a third party.
	
 	
 	

 	
 	

 	
 	

 

3

 

	

1.10	
 	

"Direct Costs"	
 	

shall mean with respect to any Drug Substance or Drug Product, the fully-burdened costs of producing (including the costs associated with product testing and release activities) and packaging of such Drug Substance and Drug Product, including the sum
of the following components: (a) the direct costs, including direct labor and materials, of producing and packaging such BIWI1; (b) all manufacturing overhead costs incurred by ImmunoGen attributable to the cost of goods under the foregoing
clause (a), including, without limitation, supervisory services, occupancy costs, purchasing, human resources, payroll, information system and accounting which are allocable to company departments based on space occupied or headcount or another
activity-based method; (c) any other costs borne by ImmunoGen for the transport, customs clearance, duty, insurance and/or storage of such Drug Substance and Drug Product; and (d) general and administrative costs which are allocable to
company departments based on space occupied or headcount or another activity-based method. Notwithstanding the foregoing, Direct Cost of Drug Substance shall not include the cost of purchasing any dedicated equipment to the extent reimbursed by BI
pursuant to Section 5.1(d) of this Agreement.
	

1.11	
 	

"DM1"	
 	

shall mean that certain maytansine derivative known as "DM1" whose specific chemical name is N2'-deacetyl-N2'(3-mercapto-1-oxopropyl)-maytansine.
	

1.12	
 	

"Drug Product"	
 	

shall mean Drug Substance, manufactured under cGMP in the final concentration for clinical use, aseptically filled in unlabeled, primary packaging material.
	

1.13	
 	

"Drug Substance"	
 	

shall mean bulk BIWI1.
	

1.14	
 	

"Effective Date"	
 	

shall mean the date first mentioned above.
	

1.15	
 	

"Field"	
 	

shall mean all human therapeutic uses.
	

1.16	
 	

"First Commercial Sale"	
 	

shall mean the date of the first commercial sale (other than for purposes of obtaining regulatory approval) of a Licensed Product by or on behalf of BI or any Sublicensee of BI.
	

1.17	
 	

"ImmunoGen Materials"	
 	

shall mean any tangible chemical, biological or research materials, including without limitation, DM1, or any assays or antibodies other than BI Materials, whether or not patentable, used by ImmunoGen or furnished by ImmunoGen to BI under this
Agreement.
	

1.18	
 	

"Improvement(s)"	
 	

shall mean any enhancement, improvement or modification to the Licensed Technology or covered by the Licensed Patent Rights which is conceived, reduced to practice or discovered during the Term of this Agreement.
	

1.19	
 	

"Indication"	
 	

shall mean shall mean one tumor type, e.g. breast cancer, lung cancer or head and neck cancer.
	

1.20	
 	

"Initiation"	
 	

shall mean, with respect to any clinical study, the start of patient treatment for such clinical study by or on behalf of BI.
	
 	
 	

 	
 	

 	
 	

 

4

 

	

1.21	
 	

"IND"	
 	

shall mean an investigational new drug application (as defined in Title 21 of the United States Code of Federal Regulations, as amended from time to time) filed or to be filed with the FDA with regard to any Licensed Product.
	

1.22	
 	

"Licensed Product(s)"	
 	

shall mean any product containing a conjugate of DM1 with an antibody or antibody derivative that is specific for the Target Antigen, including, without limitation, BIWI1, and any drug product containing such conjugate. For purposes of clarity, the
Parties hereby acknowledge and agree that a given Licensed Product that has one or more Indications shall not be considered to be a Subsequent Licensed Product for purposes of Section 3.3(d) of this Agreement.
	

1.23	
 	

"Licensed Technology"	
 	

shall mean (i) the Technology described on Schedule A attached hereto; and (ii) any Improvements thereto (other than Improvements that are Patent Rights) Controlled by ImmunoGen during the
Term of the Agreement solely to the extent accepted by BI in accordance with Section 2.3 hereof, solely to the extent that any of the foregoing relates to any Licensed Patent Rights or is necessary or useful to develop, have developed, make,
have made, sell and have sold Licensed Products.
	

1.24	
 	

"Licensed Patent Rights"	
 	

shall mean the Patent Rights in the Field in the Territory Controlled by ImmunoGen during the Term which block, absent a license, the use, making or selling of a Licensed Product. Licensed Patent Rights as of the Effective Date are described on
Schedule B attached thereto.
	

1.25	
 	

"Major Markets"	
 	

shall mean the United States of America and the European Union.
	

1.26	
 	

"Net Sales"	
 	

shall mean, as to each calendar quarter during the Term, the gross invoiced sales prices charged for all Licensed Products sold by BI and its Sublicensees to third parties throughout the Territory during such calendar quarter, less the following
amounts incurred or allowed by BI or its Sublicensees during such calendar quarter with respect to sales of Licensed Products regardless of the calendar quarter in which such sales were made:
	

 	
 	

 	
 	

(a)	
 	

trade, cash and quantity discounts or rebates actually taken and allowed, including discounts or rebates to governmental or managed care organizations;
	

 	
 	

 	
 	

(b)	
 	

credits or allowances given or made for rejection or return of previously sold Licensed Products or for retroactive price reductions (including Medicare and similar types of rebates);
	

 	
 	

 	
 	

(c)	
 	

any charges for insurance, freight and other transportation costs directly related to the delivery of Licensed Product to the extent included in the gross invoiced sales price;
	
 	
 	

 	
 	

 	
 	

 

5

 

	

 	
 	

 	
 	

(d)	
 	

any tax, tariff, duty or governmental charge levied on the sales, transfer, transportation or delivery of a Licensed Product (including any tax such as a value added or similar tax or government charge) borne by the seller thereof, other than
franchise or income tax of any kind whatsoever; and
	

 	
 	

 	
 	

(e)	
 	

any import or export duties or their equivalent borne by the seller.
	

1.27	
 	

"Patent Rights"	
 	

shall mean the rights and interests in and to any and all issued patents and pending patent applications (including inventor's certificates and utility models) in any country or jurisdiction in the Territory, including any and all provisions,
non-provisionals, substitutions, continuations, continuations-in-part, divisionals and other continuing applications, supplementary protection certificates, renewals, and all letters patent on any of the foregoing, and any and all reissues,
reexaminations, extensions, confirmations, registrations and patents of addition of any of the foregoing.
	

1.28	
 	

"Phase I Trial"	
 	

shall mean any clinical study involving the use of the Licensed Product in humans that is designed primarily to obtain preliminary safety data on the use of a Licensed Product in human patients.
	

1.29	
 	

"Phase IIa Trial"	
 	

shall mean any controlled clinical study involving the use of the Licensed Product in human patients that is designed primarily to obtain preliminary data on the effectiveness of a specific therapy involving the use of a Licensed Product in human
patients. Phase IIa Trials must take place after Phase I Trials.
	

1.30	
 	

"Pivotal Trial"	
 	

shall mean any Phase IIb/III clinical study involving a Licensed Product and having adequate statistical power to meet the requirements for regulatory approval by the FDA or the European Commission.
	

1.31	
 	

"Recognised Agents"	
 	

shall mean any third party legal entity (other than an Affiliate of BI) engaged by BI in the normal course of its business to market and/or distribute its products in a particular country of the Territory.
	

1.32	
 	

"Sublicensee"	
 	

shall mean any person, corporation, unincorporated body, or other entity including Affiliates of BI to whom BI grants a sublicense of the rights granted to BI pursuant to this Agreement. For the avoidance of doubt, Recognised Agents shall not be
considered to be Sublicensees for the purposes of this Agreement.
	

1.33	
 	

"Target Antigen"	
 	

shall mean either [ * ] and its [ * ] or, in case Section [ * ] applies,
[ * ]
	
 	
 	

 	
 	

 	
 	

 

6

 

	

1.34	
 	

"Technology"	
 	

shall mean and include any and all unpatented proprietary ideas, inventions, discoveries, data, results, formulae, designs, specifications, methods, processes, formulations, techniques, ideas, know-how, technical information (including, without
limitation, structural and functional information), process information, and any and all proprietary biological, chemical, pharmacological, toxicological, pharmacokinetic, chemical, analytical, pharmaceutical, and clinical data.
	

1.35	
 	

"Territory"	
 	

shall mean the world.
	

1.36	
 	

Valid Claim"	
 	

shall mean a claim in an issued, unexpired patent within the Licensed Patent Rights that (i) has not been finally cancelled, withdrawn, abandoned or rejected by any administrative agency or other body of competent jurisdiction and (ii) has
not been revoked, held invalid, or declared unpatentable or unenforceable in a decision of a court or other body of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal.

2.    GRANT OF RIGHTS AND RESTRICTIONS  

	2.1
	Grant of License to BI:Subject
to the terms and conditions of this Agreement, ImmunoGen grants to BI, and BI accepts, an exclusive, royalty-bearing license, including the right to grant sublicenses as described below,
within the Field and in the Territory, under the Licensed Technology and the Licensed Patent Rights and ImmunoGen's interest in any Improvements Controlled by ImmunoGen to the extent accepted in
accordance with Section 2.3 hereof, to develop, make, use and sell Licensed Products. 

	2.2
	ImmunoGen Retained Rights:Subject
to the other terms of this Agreement, ImmunoGen retains the right to use the Licensed Technology and practice the Licensed Patent Rights and to use ImmunoGen's interest in all Improvements
(i) to perform its work under this Agreement (ii) to develop, have developed, make, have made, use, have used, sell have sold, offer for sale, import, have imported, export and have
exported any product that is not a Licensed Product and (iii) for any and all uses outside of the Field. 

	2.3
	Additional Rights:

	(a)
	ImmunoGen
herewith grants to BI an exclusive option during the Term regarding all Improvements (including its interest in any Improvements owned jointly by ImmunoGen and BI)
Controlled by ImmunoGen or its Affiliates during the Term to the extent such Improvements relate to any Licensed Patent Rights or are necessary or useful to develop, have developed, make, have made,
sell and have sold Licensed Products. If BI notifies ImmunoGen in writing of its interest in the respective Improvement at any time during the Term, BI shall automatically be granted an appropriate
license so long as such Improvement is Controlled by ImmunoGen at the time of such notification, consistent with the terms of Section 2.1, which adds such Improvement to the scope of the
Licensed Patent Rights and/or Licensed Technology, as the case may be, without any additional obligations due from BI to ImmunoGen. 

7

  

	(b)
	BI
hereby grants to ImmunoGen a non-exclusive, royalty-free license under BI Intellectual Property and BI's interest in any Improvements to manufacture the
Drug Substance and Drug Product solely for delivery to BI, its Affiliates, Recognised Agents and Sublicensees for the limited duration and purposes as set forth in Section 5 below and subject
to the terms of this Agreement and the Clinical Supply Agreement attached as Schedule G. 

	2.4
	Right to Sublicense/Sub-contract and Partner; Right to License BI Improvements:

	(a)
	BI
shall have the right to grant sublicenses of its rights granted under Section 2.1 hereof to its Affiliates and other Sublicensees.

	(b)
	BI
agrees to contractually bind its Sublicensees by terms and obligations substantially similar to those applying to BI hereunder, including without limitation, BI's confidentiality
and royalty obligations.

	(c)
	BI
shall have the right to partner with third parties to co-market and/or co-promote the Licensed Products in all countries of the Territory.

	(d)
	Notwithstanding
anything herein to the contrary, BI shall be responsible for all obligations herein to be performed by it and any Sublicensee or partner. BI shall also be responsible
for any and all breaches of any obligations hereunder by any Sublicensee, Recognised Agent, partner and other subcontractor of BI.

	(e)
	BI
shall not license its interest in any Improvements to any third party, other than in connection with the grant of a sublicense to a Licensed Product or any license or sublicense to
any other product containing DM1 Controlled by BI. Subject to the foregoing, BI shall be free to use its interest in any Improvements for all purposes, including, without limitation, the sale of DM1
and DM1 intermediates to third parties. 

3.    PAYMENTS, REPORTS AND RECORDS  

	3.1
	Upfront-fee:In
consideration of the rights granted by ImmunoGen to BI hereunder, BI will pay ImmunoGen the non-refundable, non-creditable sum of  [ * ] to an account designated by ImmunoGen within 
[ * ] business days following the Effective Date.
 

8

 
	3.2
	Milestone Payments:

	(a)
	In
further consideration of the rights granted by ImmunoGen to BI hereunder, including the licenses set forth in Section 2 above, BI will pay ImmunoGen
non-refundable, non-creditable milestone payments as follows: 

	(i)	 	Pre-clinical milestones:	 	Payment
	 	 	Upon [ * ]of an US$ [ * ]in the [ * ]for a [ * ].	 	US$[**]million
	

(ii)	
 	

Clinical milestones:	
 	

Payment
	 	 	Upon[ * ] of the US$ [ * ] for a [ * ]	 	US$[**]million
	 	 	Upon [ * ] of the US$[ * ] for a [ * ]	 	US$[**]million
	 	 	Upon [ * ] of the US$[ * ] for a [ * ].	 	US$[**]million
	 	 	Upon [ * ]of the US$[ * ] in the [ * ] for a [ * ]	 	US$[**]million
	 	 	Upon [ * ] of US$[ * ] by the [ * ] for the [ * ] for a [ * ]	 	US$[**]million
	 	 	Upon [ * ] of US$[ * ] by the [ * ] for the[ * ] for a [ * ]	 	US$[**]million
	 	 	Upon [ * ] of US$[ * ] by the [ * ] in [ * ] for the [ * ] for a [ * ]	 	US$[**]million
	 	 	Upon [ * ] of US$[ * ] by the [ * ] for the [ * ] for a [ * ]	 	US$[**]million
	 	 	Upon [ * ] of US$[ * ] by the [ * ] for the [ * ] for a [ * ]	 	US$[**]million
	 	 	Upon [ * ] of US$[ * ] by the [ * ] in [ * ] for the [ * ] for a [ * ]	 	US$[**]million
	 	 	Upon [ * ] of the US$[ * ] for the [ * ] for a [ * ]	 	US$[**]million
	

(iii)	
 	

Performance milestones:	
 	

 
	

 	
 	

A [**] of:

€ [ * ] million if the [ * ] € [ * ] million

€ [ * ] million if the [ * ] € [ * ] million

€ [ * ] million if the [ * ] € [ * ] million

€ [ * ] million if the [ * ] € [ * ] million	
 	

 

	(b)
	BI
shall pay ImmunoGen the milestone payments set forth in Section 3.2(a)(i) and (ii) within  [ * ] of the occurrence of the respective milestone and the  [ * ] pursuant to Section 3.2(a)(ii) within  [ * ] of the end of the respective calendar year. The upfront-fee pursuant to Section 3.1
and
the milestone payments pursuant to Section 3.2(a)(i) and (ii) shall be paid in US Dollars. The performance milestone payments pursuant to Section 3.2(a)(iii) shall
be paid in EUROS.

	(c)
	It
is hereby understood that each milestone payment shall be paid only for the first achievement of a given milestone by a Licensed Product and that no additional milestone payments
shall be made for any subsequent achievement of such milestone by a subsequent Licensed Product. 

9

 

	3.3
	Royalty Payments:

	(a)
	In
further consideration of the rights granted by ImmunoGen to BI hereunder, including the licenses set forth in Section 2 above, BI will pay ImmunoGen a  [ * ] on [ * ] of  [ * ] by a [ * ] under a  [ * ] or [ * ] by  [ * ] as follows: 

	Annual Net Sales*
 
	 	[ * ]**
	 	[ * ]**

	 
	 	(%)
 
	 	(%)
 

	[ * ] up to [ * ]	 	[ * ]	 	[ * ]
	Above [ * ] and up to [ * ]	 	[ * ]	 	[ * ]
	Above [ * ] and up to [ * ]	 	[ * ]	 	[ * ]
	Above [ * ]	 	[ * ]	 	[ * ]

	*
	Staggered
royalties on incremental sales.

	**
	For
purposes of this Section 3.3(a), "Access" shall refer to the ability of ImmunoGen to have  [ * ] to BI's [ * ] such
that the [ * ] shall be applicable if ImmunoGen enters into a  [ * ] providing ImmunoGen with such Access. 

	(b)
	The
above royalty rates shall be payable on a country-by-country basis on the Net Sales of each Licensed Product from its First Commercial Sale until the
expiration of the royalty term as provided in Section 3.3(d). The above royalty [ * ] be  [ * ] by 
[ * ] in any
calendar year on a country-by-country basis with respect to any Licensed Product if (i) the manufacture, use or sale of such Licensed Product in such country is not
covered by a Licensed Patent Right in such country but is covered by the Licensed Technology; or (ii) (A) the Licensed Patent Right in such country covering the manufacture, use or sale
of a Licensed Product [ * ],
(B) [ * ] are [ * ]
Comparable Products in such country and (C) such third parties have, in the aggregate during such calendar year,  [ * ] or more of the
[ * ]
in such country in connection with the sale of such Comparable Product.

	(c)
	In
the event that BI, in order to exploit the licenses granted to it by ImmunoGen hereunder in any country, is required to make royalty payments to one or more third parties
(i) to obtain a license under their patent rights in the absence of which the DM1 portion of a Licensed Product could not legally be
developed, manufactured or sold in such country and/or (ii) to obtain a license under their patent rights specific to the Licensed Technology used by ImmunoGen to conjugate DM1 to antibodies,
in the absence of which any of the Licensed Patent Rights necessary to conjugate DM1 to an antibody Controlled by BI as part of a Licensed Product can not legally be practised (as evidenced, to the
extent reasonably requested by ImmunoGen, by an opinion of patent counsel), then royalties due to ImmunoGen for a given Licensed Product may be  [ * ] by [ * ]
 of the amount
of such [ * ]. Notwithstanding the following, such reductions shall in no event reduce the royalty for such
Licensed Product payable under this Section 3.3(c) to less than [ * ] of Net Sales in such country.

	(d)
	BI
shall pay royalties with respect to each Licensed Product on a country-by-country and Licensed Product-by-Licensed Product basis as
follows: 

(1) with
respect to the first Licensed Product sold by BI or any Sublicensee of BI under this Agreement (the "Initial Licensed Product") until the longer of the expiration of the last to expire
of the Licensed Patent Rights or [ * ] from date of First Commercial Sale of such Initial Licensed Product, and; 

(2) with
respect to any Licensed Product launched after the date of First Commercial Sale of the Initial Licensed Product (each, a "Subsequent Licensed Product"); 

10

 

(A) if
BI at the First Commercial Sale of the Subsequent Licensed Product is still paying ImmunoGen royalties in connection with sales of the Initial Licensed Product under
Section 3.3(a) of this Agreement, then until the longer of (i) the expiration of the last to expire of the Licensed Patent Rights covering the Subsequent Licensed Product or
(ii) [ * ] from the date of First Commercial Sale of such Subsequent Licensed Product;  provided, that, notwithstanding Section 3.3(a)
of this Agreement, the royalty rate for any Subsequent Licensed Product covered by this
Section 3.3(d)(2)(A)(ii) shall be [ * ] and; 

(B) if
BI at the First Commercial Sale of the Subsequent Licensed Product is no longer paying royalties from sales of the Initial Licensed Product under Section 3.3(a), then until the
longer of (i) the expiration of the last to expire of the Licensed Patent Rights covering the Subsequent Licensed Product or (ii) the date on which BI shall have paid royalties to
ImmunoGen from sales of any Licensed Products for an aggregate of [ * ] (whether or not such calendar quarters are
consecutive). 

	3.4
	Reports:Each
royalty payment shall be accompanied by a written report describing the Net Sales of the Licensed Product sold by or on behalf of BI, its Affiliates and Sublicensees during a "Payment Period" in
each country in the Territory in which such Licensed Product occurred in the [ * ] covered by such
statement, specifying: the [ * ] and  [ * ] in each country's currency; the applicable  [ * ]
 under this Agreement; the  [ * ] in each country's currency, including an  [ * ] of [ * ] taken in the  [ * ] of [ * ]; the  [ * ]
 to [ * ] from each  [ * ] to [ * ], under this
Section 3.4; and the [ * ] in  [ * ]. Payment Period means a  [ * ],
commencing upon the  [ * ]. 

	3.5
	Method and Manner of Royalty Payment:

	(a)
	BI
shall deliver to ImmunoGen within sixty (60) days following the end of each Payment Period a royalty report as set forth in Section 3.4 along with BI's payment to
ImmunoGen of any royalty due and payable to ImmunoGen for such Payment Period.

	(b)
	All
royalty payments shall be computed and paid in EUROS at exchange rates as published by the European Central Bank, Frankfurt am Main, Germany, and as customarily used by BI in its
regular accounting system. 

	3.6
	Withholding Tax:

	(a)
	BI
shall deduct any withholding taxes and other statutory duties from the payments agreed upon under Sections 3.1, 3.2, and 3.3 of this Agreement and pay them to the proper tax
authorities required by law applicable at the date of payment. BI shall maintain official receipts of payment of any withholding taxes and forward these receipts to ImmunoGen.

	(b)
	The
parties will exercise their best efforts to ensure that any withholding taxes imposed are reduced as far as possible under the provisions of the current or any future double
taxation agreement between the United States of America and the Federal Republic of Germany.

	(c)
	The
parties hereby acknowledge that according to German Law this reduction requires that the German Bundesamt für Finanzen issues a certificate of tax exemption.

	(d)
	The
parties hereby acknowledge that in order to achieve such reduction ImmunoGen is required to provide BI with the claim for a certificate of tax exemption in respect of royalties
performed on the official form (APPLICATION FOR TAX EXEMPTION) containing the statement of residence and Indication of the taxpayer's identification number as well as the Certificate of Filing a Tax
Return, in which it confirms that it does not derive the royalties through a permanent establishment maintained in Germany. BI agrees to provide ImmunoGen with the official form. 

11

 

	(e)
	ImmunoGen
hereby acknowledges that every three years ImmunoGen is required to submit a new Application For Tax Exemption unsolicited, which complies with the above-mentioned
prerequisites. 

	3.8
	Records:BI
and/or its Sublicensees shall keep and maintain records of sales of Licensed Product so that the royalties payable and the royalty statements may be verified. Such records shall be open to
inspection during business hours for a [ * ] period after the royalty period to which such records relate, but in
any event[ * ], by a nationally recognised independent certified public accountant selected by ImmunoGen to whom
BI has no reasonable objections and retained at ImmunoGen's expense. Said accountant shall sign a confidentiality agreement prepared by ImmunoGen and reasonably acceptable to BI and shall then have
the right to examine the records kept pursuant to this Agreement and report to ImmunoGen the findings [ * ] of
said examination of records as are necessary to evidence that the records were or were not maintained and used in accordance with this Agreement. A copy of any report provided to ImmunoGen by the
accountant shall be given concurrently to BI. If said examination of records reveals any [ * ] of the  [ * ], then BI shall promptly pay
the balance due to ImmunoGen, and if the  [ * ] is/are more than[ * ],
then BI shall also bear the expenses of said accountant. If said examination of records reveals any overpayment(s) of royalty payable, then ImmunoGen shall credit the amount overpaid against BI's
future royalty payment(s). 

	3.9
	Overdue Payments.Payments
not paid within the time period set forth in this Section 3 shall bear interest at a rate of [ * ]
per [ * ] from the due date until paid in full. 

4.    DEVELOPMENT AND COMMERCIALISATION  

	4.1
	Development Responsibility:

	(a)
	Except
as otherwise set forth in this Agreement, BI shall solely be responsible for the development of the Licensed Product for the Field as provided hereunder, including but not
limited to any and all pre-clinical development activities, clinical studies and other testing and work conducted in connection with the Licensed Product for the Field, at BI's own expense
and BI shall be solely responsible for making decisions related hereto.

	(b)
	If
prior to any [ * ] by BI with respect to a given License Product, BI determines, in its
reasonable discretion, that the [ * ] of such Licensed Product using the  [ * ] has [ * ]
, then BI
shall have the right, upon not less than [ * ] prior written notice to ImmunoGen, to  [ * ] as the [ * ]
 without
any additional obligations due from BI to ImmunoGen. Any decision regarding the [ * ] of development of a Licensed
Product that is [ * ] to the  [ * ] is in the [ * ] of BI. 

	4.2
	Development Obligation:

	(a)
	After
the Effective Date, BI shall use its [ * ] and shall accept the corresponding
responsibility, at its sole cost and expense, for the development, safety of, and all required periodic reporting to Competent Authorities required to obtain all regulatory approvals for, the Licensed
Product(s) for the Field in the Major Market countries.

	(b)
	After
the Effective Date, BI shall provide to ImmunoGen regular written reports every [ * ],
setting forth (i) significant developments with respect to Licensed Product, and (ii) the status and progress of the development and/or registration activities related to the Licensed
Product. 

12

 

	(c)
	BI
shall promptly advise ImmunoGen in writing upon the filing for regulatory approval to market a Licensed Product, and upon receipt of regulatory approval to market a Licensed
Product, in each case in each country of the Territory.

	(d)
	ImmunoGen
shall use [ * ] to  [ * ] and [ * ] the  [ * ]
 for Drug Product to meet BI's requirements for conduct of clinical trials, according to the development plan
attached as Schedule F and thereby agrees to maintain the basic assumptions included in Schedule F  which may be amended by the Parties during the
development. During this [ * ] and  [ * ], ImmunoGen will keep BI informed on a regular basis and BI shall be entitled to advise and
contribute to
such process, as appropriate.

	(e)
	ImmunoGen
shall provide the necessary documentation and assist BI in preparation of the chemical, pharmaceutical, and analytical sections of regulatory submissions for IND or foreign
equivalent. 

	4.3
	Marketing Efforts:

	(a)
	BI
will use its Commercially Reasonable Efforts during the Term of this Agreement to commercialise a Licensed Product in each Major Market in which such Licensed Product is approved
for marketing. Notwithstanding BI's right to terminate in 13.3, BI shall not discontinue such efforts for any reason other than Force Majeure, mutual agreement of the parties and/or material adverse
side effects in rendering such Licensed Product unsuitable as a medicine for human use.

	(b)
	With
respect to each country in the Territory that is not a Major Market, BI shall have the right to determine, in its sole judgement, whether and to what extent it will commercialise
the Licensed Product in each such country in which the Licensed Product is approved for marketing.

	(c)
	All
commercialisation efforts undertaken by BI's Affiliates, Sublicensees and Recognised Agents hereunder shall be attributable to BI. 

	4.4
	Effect of Failure to Use Commercially Reasonable Efforts.  In the event that BI fails to use Commercially Reasonable Efforts as described in Section 4.3(a), then
ImmunoGen shall have the right to terminate the Agreement in
accordance with Section 13.2. 

5.    SUPPLY AND MANUFACTURING OBLIGATIONS  

	5.1
	Non-clinical Material; Clinical Material; Dedicated Equipment

	(a)
	During
the Term of this Agreement, ImmunoGen will supply BI with its requirements of Drug Substance in non-GLP and GLP quality as well as assays and reagents for the
determination of DM1 conjugate and free DM1 and DM1 derivatives in biological material and in Drug Substance preparations in order for BI to carry out the non-clinical development of the
Licensed Products, as listed on Schedule D attached hereto. BI will pay ImmunoGen a transfer price for such non-clinical Drug Substance equal to  [ * ] of ImmunoGen's Direct Cost of Drug
Substance. In addition, ImmunoGen will provide BI with data showing at
least a [ * ] of the Drug Product in its  [ * ]. A stability program will be initiated and continue until the earlier of the Term of the
Agreement or until
samples are used up. For GLP material, ImmunoGen will provide a Certificate of Analysis for each batch manufactured.

	(b)
	In
the event that, over a given calendar year, ImmunoGen fails to supply BI with at least [ * ]
of its requirements of non-clinical Drug Substance for that calendar year in the amounts as specified in
Schedule D and such failure is not attributable to a contingency set forth in Section 15.3 or BI's failure to supply an adequate amount of BIWA4 in a timely manner, then, 

13

 

subject
to the final sentence of this Section 5.1(b), ImmunoGen shall forgo certain milestone payments as follows. If such failure to supply occurs  [ * ] of [ * ]
, then
ImmunoGen shall forgo the [ * ] and  [ * ] to Section 3.2. If such  [ * ]
to [ * ] occurs  [ * ] of [ * ], then
ImmunoGen shall forgo the [ * ] and  [ * ] pursuant to Section 3.2. The foregoing notwithstanding, ImmunoGen shall have 
[ * ] from the [ * ] of the
calendar year to [ * ] such failure and not forgo any milestone payments. 

	(c)
	In
addition, ImmunoGen shall supply BI with such quantities of Drug Product in order for BI to conduct clinical development activities until conclusion of Phase I Trials and Phase IIa
Trials. The terms and conditions of the supply of Drug Product shall be governed by the Clinical Supply Agreement between ImmunoGen and Boehringer Ingelheim Pharma KG ("BI Pharma") attached hereto as  Schedule G.

	(d)
	If
ImmunoGen determines that it is necessary or advisable to purchase dedicated equipment in order to manufacture non-clinical Drug Substance for BI, BI will reimburse
ImmunoGen for the cost of procuring such dedicated equipment subject to BI's prior written approval. In case of termination, ImmunoGen shall permit BI to remove such dedicated equipment at BI's sole
cost and expense.

	(e)
	The
audit rights in Section 8.1.2 and 8.1.3 of the Clinical Supply Agreement shall also apply for non-clinical material. 

	5.2
	Technology Transfer.As
soon as reasonably practicable following the Effective Date, ImmunoGen will transfer to BI and its agents such Technology within its Control related to the Licensed Technology and provide such
technical assistance as may be reasonably required by BI for the manufacture of Licensed Products in accordance with the Technical Transfer Plan to be agreed upon by BI and ImmunoGen before
May 31, 2002, the major terms of which are attached hereto as Schedule E.

6.    PRODUCT INQUIRIES, COMPLAINTS AND ADVERSE EVENTS  

	6.1
	Medical/Scientific Product Inquiries:

	(a)
	BI
shall be solely responsible for responding to all medical questions and inquiries relating to the Licensed Products in each country in the Territory.

	(b)
	In
conjunction with the marketing and sale of Licensed Products in a country in the Territory, BI shall be solely responsible for providing (i) medical, technical and
scientific information concerning Licensed Product to healthcare professionals, managed care organisations, sales representatives, medical publishers, consumers, patient assistance programs and others
who may request such information, and (ii) after-hours coverage to address emergency requests for medical, technical and such scientific information concerning the Licensed Products. 

	6.2
	Adverse Medical Events and Complaints:BI
agrees to provide ImmunoGen with Adverse Event information and product complaint information relating to Licensed Products as compiled and prepared by BI in the normal course of business in
connection with the development, commercialization or sale of any Licensed Product, within time frames consistent with reporting obligations under applicable laws and regulations. ImmunoGen agrees to
provide BI with Adverse Event and product complaint information relating to any product containing DM1 that is compiled and prepared by ImmunoGen or any third party in the normal course of business in
connection with the development, commercialization or sale of any such product, within time frames consistent with reporting obligations under applicable laws and regulations; provided, however, that
the foregoing shall not require ImmunoGen to violate any agreements with or confidentiality obligations owed to any third party. ImmunoGen, in each third 

14

 

party
contract in which it has granted or will grant a license under the Licensed Technology and Licensed Patent Rights, has included or will include, as the case may be, a provision requiring each
such third party to provide reports of Adverse Events related to the product that is the subject of such license agreement. ImmunoGen will review and assess these reports and will communicate to BI
all resulting information which is relevant for the safety of the Licensed Product and its use to BI. ImmunoGen hereby affirms to BI that such communication is not within the confidentiality
obligations ImmunoGen owes to any third party. BI shall provide its Adverse Event and product complaint information hereunder to ImmunoGen's designated representative, who shall be its Chief
Regulatory Officer unless ImmunoGen otherwise notifies BI. ImmunoGen shall provide its Adverse Event and product complaint information hereunder to BI's designated representative, who shall be the
head of its Drug Safety group in BI's Medical Affairs Department unless BI otherwise notifies ImmunoGen. 

7.    RIGHTS AND IMPROVEMENTS  

	7.1
	Ownership of Technology and Proprietary Materials:All
BI Intellectual Property and BI Materials shall be sole and exclusive property of BI and may be used by BI in any manner BI, in its sole discretion, deems appropriate to exercise its rights under
this Agreement. All Licensed Technology and ImmunoGen Materials shall be sole and exclusive property of ImmunoGen and may be used by ImmunoGen in any manner ImmunoGen, in its sole discretion, deems
appropriate, to exercise its rights under this Agreement, subject to the grant of the licenses to BI described in this Agreement. 

	7.2
	Improvements:

	(a)
	ImmunoGen
will disclose promptly to BI any and all Improvements conceived or made by or for it or otherwise coming under its Control during the Term of this Agreement to the extent
such Improvements are related to any Licensed Patent Rights or are necessary or useful to develop, have developed, make, have made, sell and have sold Licensed Products.

	(b)
	To
the extent any Improvement was conceived or made jointly by or for ImmunoGen and BI (a "Joint Improvement"), such Joint Improvement shall be owned jointly by ImmunoGen and BI.
ImmunoGen and BI each hereby represents that all employees and other persons acting on its behalf in performing its obligations under this Agreement shall be obligated under a binding written
agreement or the applicable law to assign to it or as it shall direct all inventions made or developed by such employees or other persons.

	(c)
	To
the extent any Improvement was conceived or made by or for one party, the Improvement shall be owned exclusively by such party. 

8.    PATENTS AND TRADEMARKS  

	8.1
	Patent Prosecution:

	(a)
	ImmunoGen
agrees to use commercially reasonable effort to continue, at its sole cost and expense, the prosecution and maintenance of the Licensed Patent Rights; provided, however,
that ImmunoGen shall keep BI fully and timely informed in respect of the course and conduct of patent application
prosecution matters pertaining to Licensed Products. Prosecution and maintenance of Licensed Patent Rights shall include, but not be limited to, prosecuting pending patent applications therein and
maintaining and extending patents therein, including in any defensive proceedings such as oppositions and the like and any reissue or re-examination proceedings, in any country in the
Territory should such actions be reasonably deemed necessary or desirable by ImmunoGen. ImmunoGen shall keep BI advised of the 

15

 

status
of such prosecution and maintenance by timely providing BI with copies of all patent applications and patents, and all official communications with respect to such patent applications and
patents, contained in the Licensed Patent Rights for the purpose of obtaining substantive comment of BI patent counsel. 

	(b)
	As
regards any Patent Rights covering Joint Improvements, ImmunoGen will have the first right, but not the obligation, to undertake filing(s), prosecution and maintenance of
inventorship certificate(s), patent application(s) and patent(s) thereon. ImmunoGen shall advise BI within thirty (30) days whether it will file any such patent application with respect to any
Joint Improvements. If ImmunoGen fails to undertake the filing(s) of any such patent application within sixty (60) days after receipt of written notice from BI that it believes filing(s) of
such an application by ImmunoGen is appropriate, BI may undertake such filing(s) at its own expense. In connection with any such filing(s), the filing party will file, prosecute and maintain such
patent application in the name of both parties jointly.    In any case, the filing party (i) will provide the non-filing party with a copy of any such proposed patent
application for review and comment reasonably in advance of filing, and (ii) will keep the non-filing party reasonably informed of the status of such filing, prosecution and
maintenance. Costs of any such filing, prosecution and maintenance shall be shared jointly by the parties. 

	8.2
	Patent Abandonment:If
ImmunoGen elects to abandon any patent application or patent included within the Licensed Patent Rights, and/or terminate its future obligations to prosecute and maintain any such patent
application or patent, then it shall provide BI with [ * ] prior written notice of its election. If BI notifies
ImmunoGen within such [ * ] response period, that it wishes to prosecute or maintain such patent application or
patent at its own expense, then ImmunoGen shall promptly transfer and assign such patent application or patent to BI and continue to prosecute and maintain such patent application or patent or until
such transfer and assignment become effective. Upon such transfer and assignment becoming effective, such patent application or patent shall no longer be considered to be included within the Licensed
Patent Rights, and ImmunoGen and its employees shall thereafter reasonably assist BI in the prosecution and maintenance of such patent application or patent; provided, however, that such assistance
shall be subject to BI's reimbursement of ImmunoGen's out-of-pocket expenses with respect thereto. 

	8.3
	Trademarks:BI,
in its sole discretion, in its own name and at its own expense, may prepare or develop, adopt and register all trademarks, trade names, brand names and logos for use with the Licensed Products.
These trademarks, trade names, brand names and logos shall be and shall remain the sole and exclusive
property of BI. All use of such trademarks, trade names, brand names and logos shall inure to the sole benefit of BI. BI shall remain the owner of the trademarks, trade names, brand names and logos
and the goodwill associated with the same and ImmunoGen agrees not to assert any ownership interest in such trademarks, trade names, brand names and logos or the goodwill associated therewith. 

16

   9.    INFRINGEMENT  

	9.1
	Infringement of Third Parties' Rights:

	(a)
	Notice. If the development, registration, manufacture, use, marketing or sale of the Licensed Products results in a claim against a
party of infringement or misappropriation of any third party's patent or other intellectual property right ("Third-Party Claim"), the party first having notice of a Third-Party Claim shall promptly
notify the other party in writing specifying in reasonable detail the alleged grounds or basis for the Third-Party Claim (to the extent known).

	(b)
	Patent Infringement Claims. If the development, registration, manufacture, use, marketing or sale of Licensed Products in a country in
the Territory results in a Third-Party Claim of patent infringement, the parties agree to respond to and/or defend against the Third-Party Claim as follows:

	(i)
	Control of Defence. ImmunoGen shall have the initial right to manage solely the defence of the parties
against the Third-Party Claim. If ImmunoGen elects to exercise such right as to the Third-Party Claim, BI shall cooperate with ImmunoGen at ImmunoGen's request and shall have the right to be
represented by counsel selected and paid for by BI. If ImmunoGen elects not to exercise such right as to the Third-Party Claim, BI shall have the right to manage solely the defence of the parties
against the Third-Party Claim and ImmunoGen shall cooperate with BI at BI's request and shall have the right to be represented by counsel selected by ImmunoGen.

	(ii)
	Settlements. The party that manages solely the defence of the parties against the Third-Party Claim
shall also have the right to settle such Third-Party Claim on terms deemed appropriate by such party provided, however, that (A) neither party shall settle any Third-Party Claim in a manner
that is prejudicial to the Licensed Products, (B) such party shall consult with the other party concerning the terms of any settlement agreement before entering into such an agreement, and
(C) neither party shall settle any such Third-Party Claim without the prior written consent of the other party, which consent shall not be unreasonably withheld.

	(iii)
	Costs of Defence. Each party shall be responsible for its own fees and costs of attorneys and
consultants, together with the court costs, incurred in defending against the Third-Party Claim. 

	9.2
	Infringement Claims against Third Parties:ImmunoGen
agrees during the Term of this Agreement to take reasonable actions to protect the Licensed Patent Rights from infringement and the Licensed Technology from unauthorised possession or use. 

	(a)
	A
party first having knowledge of any infringement or misappropriation, or knowledge of a reasonable probability of such infringement or misappropriation, by a third party, including
that contained in a notice provided under the 1984 Act by a party filing an ANDA or Paper NDA for Licensed Products, or an equivalent action in any other country of the world, shall promptly notify
the other party in writing. ImmunoGen shall institute, prosecute, and control, at its own expense and with counsel of its own choosing, any action or proceeding against the third party with respect to
such infringement or misappropriation, and keep BI informed of the progress of such enforcement proceeding and shall give due consideration to the suggestions or comments of BI in connection
therewith.

	(b)
	If
ImmunoGen fails to act within a period of [ * ] after receiving notice of the infringement in
a country in the Territory, BI shall have the right to bring and control, at its own expense, 

17

 

any
such action by counsel of its own choice. If BI brings any such action or proceeding, ImmunoGen may be joined as a party plaintiff and ImmunoGen agrees to give BI reasonable assistance to file
and to prosecute such suit. 

	(c)
	To
the extent that ImmunoGen or BI initiates and prosecutes a proceeding under Section 9.2 on its own, without the material assistance of or the participation as a
co-plaintiff in the action by the other party, then the party that prosecuted the action shall be entitled to retain for its sole and exclusive benefit any damages or other monetary award
recovered therein in its favour.

	(d)
	To
the extent that both ImmunoGen and BI materially assist or participate in, or, pursuant to Section 9.2(b) above, are both parties to, any such proceeding, then:

	(i)
	the
costs and expenses of each of ImmunoGen and BI under this Section 9.2(d) shall be reimbursed to each party pro rata, based on the actual
amounts spent by such party, out of any damages or other monetary awards recovered therein in favour of ImmunoGen and/or BI; and

	(ii)
	the
amount of any damages or other monetary awards recovered therein in favour of ImmunoGen and/or BI, in excess of the reimbursement provided for in
clause (i) above, shall be divided as follows: (1) first, to BI, as reimbursement for [ * ]
associated with Licensed Products and to ImmunoGen as reimbursement for [ * ] solely to the extent that the award
or compensation is attributable to [ * ] associated with Licensed Products; and (ii) second, any amounts
remaining shall be allocated as follows: (a) if ImmunoGen is the party prosecuting such action, [ * ] to
ImmunoGen, (b) if BI is the party prosecuting such action, [ * ] to BI and  [ * ] to ImmunoGen, and (c) if both parties are
prosecuting such action,  [ * ] to each party. 

10.    REPRESENTATIONS AND WARRANTIES  

	10.1
	ImmunoGen Representations:ImmunoGen
represents and warrants to BI that: 

	(a)
	No Conflict. The execution, delivery and performance of this Agreement by ImmunoGen does not conflict with any agreement, instrument or
understanding, oral or written, to which it is a party or by which it may be bound, and does not violate any law or regulation of any court, governmental body or administrative or other agency having
authority over it, including, without limitation, 35 U.S.C.A. Sections 203 and 204. ImmunoGen is not currently a party to, and during the Term of this Agreement will not enter into, any agreements,
oral or written, that are inconsistent with its obligations under this Agreement.

	(b)
	Authority. ImmunoGen is validly existing and in good standing under the laws of the state of its incorporation and has the corporate
power and authority to enter into this Agreement. The execution, delivery and performance of this Agreement have been duly authorized by all necessary action on the part of ImmunoGen, its officers and
directors.

	(c)
	Ownership. To ImmunoGen's knowledge, all of the Licensed Patents are subsisting and are valid and enforceable. ImmunoGen (i) has
not previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest in Licensed Patents, or any component of the Licensed Technology, and (ii) has no knowledge
of the existence of any patent, trademark or other intellectual property right (other than any patent application) owned or controlled by ImmunoGen, other than the Licensed Patent Rights, in case of
either (i) or (ii), that would prevent ImmunoGen and BI from manufacturing and supplying Licensed Products, and BI from exploiting its rights granted under Section 2.1. In addition,
ImmunoGen has no 

18

 

knowledge
of the existence of any patent or intellectual property right (other than any patent application) owned or Controlled by a third party that would materially conflict with the grant of the
license set forth in Section 2.1 of this Agreement. 

	(d)
	Litigation. There are no claims, judgements or settlements against, pending with respect to the Licensed Patents or any component of
Licensed Technology. In addition, to ImmunoGen's knowledge, no such claims, judgements or settlements are threatened.

	(e)
	Further Warranties:ImmunoGen
covenants to BI that: 

	(i)
	The
development and manufacture of DM1 by ImmunoGen under this Agreement shall be in compliance with the laws, requirements and regulations applicable
thereto in the Territory.

	(ii)
	The
documentation to be provided to BI pursuant to Section 5.2 will, at the time of transfer to BI, contain all material know-how
and information then in ImmunoGen's Control relating to the production of Licensed Products.

	(iii)
	All
Certificate of Analysis documents which will be provided to BI under this Agreement shall be generated and documented in accordance with generally
accepted standards of the pharmaceutical industry.

	(iv)
	All
written information, submitted to BI by ImmunoGen in response to due diligence investigation, regarding Licensed Technology and Licensed Patent
Rights is, to the best of ImmunoGen's knowledge, accurate in all material respects. 

	10.2
	BI Representations and Warranties:BI
represents, warrants and covenants to ImmunoGen that: 

	(a)
	No Conflict. The execution, delivery and performance of this Agreement by BI does not conflict with any agreement, instrument or
understanding, oral or written, to which it is a party or by which it may
be bound, and does not violate any law or regulation of any court, governmental body or administrative or other agency having authority over it. BI is not currently a party to, and during the term of
this Agreement will not enter into, any agreements, oral or written, that are inconsistent with its obligations under this Agreement.

	(b)
	Authority. BI is validly existing and in good standing under the laws of the state of its incorporation and has the corporate power and
authority to enter into this Agreement. The execution, delivery and performance of this Agreement have been duly authorized by all necessary action on the part of BI, its officers and directors. 

	10.3
	Warranty Disclaimer.Except
as otherwise expressly provided in this agreement, neither party makes any warranty with respect to any technology, goods, services, rights or other subject matter of this Agreement and hereby
disclaims warranties of merchantability, fitness for a particular purpose and noninfringement with respect to any and all of the foregoing. 

11.    INDEMNIFICATION  

	11.1
	Indemnification by the Parties:Each
party (the "Indemnitor") will indemnify the other party (the "Indemnitee") against any liability in connection with any claim, suits, liabilities, etc. arising out of the performance by the
Indemnitor of its work under the Agreement or the exploitation by the Indemnitor of its rights under the Agreement, including, without limitation, the development, manufacture, promotion, or sale of 

19

 

Licensed
Products, unless such liability results from (i) the negligence or wilful misconduct of the Indemnitee or (ii) a breach of the warranties set forth in the Agreement by the
Indemnitee. 

	11.2
	Indemnification Procedures:

	(a)
	The
Indemnitee shall: (i) notify the Indemnitor of any liability and full details of the basis therefor with respect to which the Indemnitee intends to claim indemnification as
soon as practicable after the
Indemnitee becomes aware of any such liability; (ii) permit the Indemnitor to assume the defence thereof; and (iii) cooperate with the Indemnitor, at the Indemnitor's expense, in the
defence thereof.

	(b)
	With
respect to any matter for which the Indemnitor has an obligation to indemnify the Indemnitee under this Agreement, the Indemnitee shall have the right to participate and be
represented (at the Indemnitor's expense) by legal counsel of the Indemnitee's choice in all proceedings and negotiations, if representation by counsel retained by Indemnitor would be inappropriate
due to actual or potential differing interests between the Indemnitee and any other party represented by such counsel in such proceedings.

	(c)
	The
indemnity agreement in this Section 11 shall not apply to amounts paid in settlement of any liability if such settlement is effected without the consent of the Indemnitor,
which consent shall not be unreasonably withheld.

	(d)
	Failure
of the Indemnitee to deliver notice to the Indemnitor within thirty (30) days after becoming aware of a liability shall relieve the Indemnitor of any liability to the
Indemnitee pursuant to this Section 11 in the event, but only to the extent, such delay is prejudicial to the Indemnitor's ability to defend such action. 

12.    CONFIDENTIALITY  

	12.1
	Confidential Information:All
data, information, documents and materials transmitted by BI to ImmunoGen or by ImmunoGen to BI in conjunction with this Agreement, including, but not limited to, all scientific, technical and
clinical data, information reports, financial or business records, forecasts, orders, summaries and information gathered, generated or transferred by a party during the course of this Agreement is
considered confidential and proprietary information of the disclosing party (hereinafter "Confidential Information"). The parties shall use the Confidential Information only for the purpose of
executing their rights and fulfilling their obligations under this Agreement. 

	12.2
	Disclosure:

	(a)
	Upon
execution of this Agreement and thereafter on an ongoing basis during the Term of the Agreement, each party shall disclose to the other party, in confidence, subject to the terms
of this
Section 12, information required by the other party in order to execute its rights and fulfil its obligations pursuant to this Agreement. Notwithstanding the foregoing, a party shall not be
obligated to disclose to the other party any information that it is prohibited from disclosing to the other party, either by reason of a contract with a third party or by law. In the event of such a
restriction, the parties shall cooperate and take such legally permissible action as may be reasonable to permit such disclosure to be made.

	(b)
	The
receiving party shall not disclose, without prior written consent of the disclosing party, any Confidential Information to any third party other than officers, directors,
Affiliates and representatives of the receiving party and to third parties mentioned in Section 2.4. When the receiving party does disclose information, it will only be on a need to know basis,
including, without limitation, fulfilment of corporate reporting required by law or regulation, hospital authorities, regulatory authorities and others who have agreed in writing to observe the 

20

 

confidentiality
of Confidential Information in the same manner and to the same extent as provided in this Section 12. 

	12.3
	Publications

	(a)
	In
recognition of BI's assumption of development and marketing responsibilities in connection with the Licensed Product, and in order to assure consistency with BI's marketing plans,
except for submissions of manuscripts, abstracts or other publications made prior to the Effective Date, ImmunoGen, its Affiliates, their employees, clinical investigators or consultants shall not
have the right to make any public disclosure of information, whether oral or in writing, concerning the pre-clinical and/or clinical trial activities and/or results pertaining specifically
to Licensed Products without the express written consent of BI, which consent may be withheld in BI's sole discretion. BI shall be entitled to publish scientific information and data, including the
results of clinical trials, as it deems appropriate, to advance the commercialization of the Licensed Product, subject to subsection (b) below.

	(b)
	Notwithstanding
the foregoing, BI shall consult with ImmunoGen prior to the submission of any manuscript for publication if the publication will contain any Confidential Information
of ImmunoGen, unless the applicable laws and regulations prohibit such consultation. Such consultation shall include providing a copy of the proposed manuscript to ImmunoGen at least  [ * ]
prior to the proposed date of submission to a publisher, incorporating appropriate changes proposed by
ImmunoGen regarding its Confidential Information into the manuscript submission and deleting all Confidential Information of ImmunoGen as it may request; provided, however, that ImmunoGen's review
hereunder shall be deemed completed at the end of such [ * ] period. 

	12.4
	Obligation to Obtain Agreements:The
obligations of the receiving party regarding the confidentiality and nondisclosure of Confidential Information shall extend to and be binding upon all employees or agents of the receiving party
who
have access to Confidential Information pursuant to this Agreement as if such employees or agents were parties hereto. 

	12.5
	Exceptions:The
obligations of the receiving party regarding the confidentiality and nondisclosure of information as provided in this Section 12 shall not apply to certain information if it can be
demonstrated by written documentation or other adequate proof that such information: 

	(a)
	Is
already known to the receiving party as shown by competent written records;

	(b)
	Is
or becomes publicly available through no fault of the receiving party;

	(c)
	Is
disclosed to the receiving party by a third party not subject to an obligation of confidentiality to the disclosing party respecting such information;

	(d)
	Is
required to be disclosed by law, regulation, order, decree or subpoena or other legal process; provided that the receiving party has used reasonable efforts to obtain a protective
order and has taken reasonable actions to avoid further disclosure of such information to any party not part of such requirement; or

	(e)
	Is
independently developed by the receiving party without reliance on information provided by the disclosing party as shown by competent written records. 

	12.6
	Public Disclosure:Neither
ImmunoGen nor BI shall issue a press release or in any other way announce to the public the existence, terms, conditions of, or performance under this Agreement without the prior written
consent of the other party, which consent shall not be unreasonably withheld or delayed, unless the 

21

 

existence,
terms, conditions of, or performance under this Agreement is required to be disclosed by law, regulation, order, decree or subpoena or other legal process; provided that the party ordered
to so announce has used reasonable efforts to obtain a protective order or other applicable protection against further disclosure or release or announcement of such information. The parties shall
mutually agree on the text of a press release announcing the execution of this Agreement and on any confidential treatment request(s) to be filed with the Securities and Exchange Commission with
respect
to this Agreement. Once any written text is approved for disclosure by both parties as provided herein, either party may make subsequent or repeated public disclosures of the contents thereof without
the further approval of the other party. Nothing in the foregoing, however, shall prohibit a party from making such disclosures regarding this Agreement or the terms thereof to the extent deemed
necessary under applicable federal or state securities laws or any rule or regulation of any nationally recognized securities exchange, subject to the terms of Section 12.5 above regarding
disclosures required to comply with applicable laws, regulations or court order. 

13.    TERM AND TERMINATION  

	13.1
	Term:Unless
earlier terminated pursuant hereto, the term of this Agreement (the "Term") shall continue on a country-by-country basis through the last to expire of any obligation of
BI to pay a royalty to ImmunoGen hereunder in such countries in the Territory. However, in the European Union the obligation of ImmunoGen not to license or exploit by itself the Licensed Technology
shall expire on a country-by-country basis after expiration of the Licensed Patent Rights in the respective country or after ten (10) years from First Commercial Sale of
the respective Licensed Product, whichever is the longer. 

	13.2
	Early Termination:Notwithstanding
Section 13.1, either party may, in addition to exercising any other available legal or equitable rights or remedies, terminate this Agreement, effective immediately upon the
expiration of any applicable cure period, upon the occurrence of an Event of Default (as defined below) with respect to the other party. The term "Event of Default" with respect to a party means the
occurrence of any of the following events: 

	(a)
	Unless
earlier terminated pursuant hereto, the term of this Agreement (the "Term") shall continue on a country-by-country basis through the last to expire of
any obligation of BI to pay a royalty to ImmunoGen hereunder in such countries in the Territory. However, in the European Union the obligation of ImmunoGen not to license or exploit by itself the
Licensed Technology shall expire on a country-by-country basis after expiration of the Licensed Patent Rights in the respective country or after ten (10) years from
First Commercial Sale of the respective Licensed Product, whichever is the longer.

	(b)
	A
party (i) becomes unable to pay its debts as they mature, (ii) is the subject of a voluntary or involuntary petition in bankruptcy or of any other proceeding under
bankruptcy, insolvency or similar laws which, if involuntary, is not dismissed within [ * ] of the date filed,
(iii) makes an assignment for the
benefit of creditors, (iv) is named in, or its property is subject to, a suit for the appointment of a receiver which is not dismissed within  [ * ] of the date filed, or (v) is
dissolved or liquidated. 

	13.3
	Termination by BI:BI
has the right to terminate this Agreement for any reason at any time upon ninety (90) days' advance written notice given to ImmunoGen. 

22

 

14.    EFFECTS OF TERMINATION  

	14.1
	Further Licenses/Reversion of Rights:

	(a)
	Upon
the expiration of this Agreement pursuant Section 13.1, on a country by country basis, BI shall have a non-exclusive, irrevocable, fully paid-up,
royalty free license to use and exploit the Licensed Technology in such country.

	(b)
	In
the event this Agreement is terminated by BI in accordance with Section 13.2(a) of this Agreement as a result of the grant by ImmunoGen to a third party of a license under
the Licensed Technology and/or Licensed Patent Rights in violation of the exclusive license granted to BI under Section 2.1, BI's license under Section 2.1 of this Agreement shall
thereafter become a perpetual, royalty-free, fully-paid license.

	(c)
	In
the event this Agreement is terminated for any other reason other than as described in Section 14.1(a) and (b) above, all rights granted to BI under
Section 2.1 shall terminate and revert to ImmunoGen. 

	14.2
	Inventory:If
either party terminates this Agreement, then BI shall have the right, within [ * ] after such termination, to
sell off its remaining inventory of Licensed Product and pay ImmunoGen all royalties on account thereof. 

	14.3
	Other Penalties:

	(a)
	Termination
of this Agreement by either party shall not prejudice the rights of such party under this Agreement, at law or in equity or otherwise, to seek damages or injunctive relief
for any breach of this Agreement by the other party hereto and all payment obligations accruing under this Agreement prior to the effective date of termination.

	(b)
	Except as otherwise provided in this Agreement, neither ImmunoGen nor BI will be liable with respect to any subject matter of this
Agreement under any contract, negligence, strict liability or other legal or equitable theory for any punitive damages or indirect, incidental, consequential damagesor lost profits, including, without
limitation, cost of procurement of substitute goods or technology, or loss of opportunity, loss of income or compensation for loss of goodwill. 

	14.4
	Accrued Rights:Termination
of this Agreement for whatever reason shall not affect the accrued rights of either ImmunoGen or BI arising under or out of this Agreement. The obligations under any other provision that
expressly or by implication are intended to survive expiration or termination shall survive expiration or termination of this Agreement. 

	14.5
	Confidential Information.Upon
the expiration or termination of this Agreement, the receiving party will upon request from the disclosing party promptly return to the disclosing party all of the Confidential Information in the
receiving party's possession, as well as all written information and materials that incorporate Confidential Information; provided,  however, that the
receiving party may keep (i) all information and material that incorporate Confidential Information necessary to exploit the
receiving party's rights set forth in Section 14 and/or (ii) one (1) copy of such Confidential Information, or as required by applicable laws, rules or regulations, subject to the
confidentiality provisions contained herein. 

23

 

15.    MISCELLANEOUS  

	15.1
	Either
party shall not be entitled to assign or otherwise transfer its rights and obligations under this Agreement in whole or in part to any third party without the prior written
consent of the other party.

	15.2
	This
Agreement set forth the entire agreement between the parties and supersedes all previous agreements, written or oral regarding the subject matter hereof. This Agreement may be
amended only by an instrument in writing duly executed on behalf of the parties.

	15.3
	Neither
party shall be liable for delay or failure to perform hereunder due to any contingency beyond its control, including but not limited to acts of God, fires, floods, wars,
civil wars, sabotage, strikes, governmental laws, ordinances, rules or regulations or failure of third party delivery, provided, such party promptly gives to the other party hereto written notice
claiming for force majeure and uses its best efforts to eliminate the effect of such force majeure, insofar as is possible and with all reasonable dispatch. If the period of delay or failure should
extend for more than [ * ] then either party shall have the right to terminate this Agreement forthwith upon
written notice at any time after expiration of said [ * ] period.

	15.4
	Any
waiver shall be made in writing for it to be effective and unless expressly stated shall not be a continuing waiver nor shall it prevent the waiving party from acting upon that
or any subsequent breach or from enforcing any term or condition of this Agreement.

	15.5
	The
invalidity of any provision of this Agreement or any loophole in this Agreement shall not affect the validity of any other provision hereof. The parties undertake to replace the
invalid provision or close the loophole in the Agreement with another provision which reflects legally the originally intended commercial objectives of the parties as closely as possible.

	15.6
	This
Agreement shall be governed exclusively by German laws. In the event of any controversy or claim arising out of or relating to any provision of this Agreement, the parties shall
first try to settle those conflicts amicably between themselves. Any dispute, controversy or claim initiated by either party arising out of, resulting from or relating to this Agreement, or the
performance by either party of its obligations under this Agreement (other than bona fide third party actions or proceedings filed or instituted in an action or proceeding by a third party against a
party), whether before or after termination of this Agreement, shall be finally resolved by binding arbitration. Whenever a party shall decide to institute arbitration proceedings, it shall give
written notice to that effect to the other party. Any such arbitration shall be conducted under the commercial arbitration rules of the ICC by a panel of three arbitrators appointed in accordance with
such rules. Any such arbitration shall be held in [ * ]. The arbitrators shall have the authority to grant
specific performance and to allocate between the
parties the costs of arbitration in such equitable manner as they determine. Judgment upon the award so rendered may be entered in any court having jurisdiction or application may be made to such
court for judicial acceptance of any award and an order of enforcement, as the case may be. In no event shall a demand for arbitration be made after the date when institution of a legal or equitable
proceeding based upon such claim, dispute or other matter in question would be barred by the applicable statute of limitations. Notwithstanding the foregoing, either party shall have the right,
without waiving any right or remedy available to such party under this Agreement or otherwise to seek and obtain from any court of jurisdiction any interim or provisional relief that is necessary or
desirable to protect the rights or property of such party, pending the selection of the arbitrators hereunder or pending the arbitrators' determination of any dispute, controversy or claim hereunder.

	15.7
	In
the performance of this Agreement each party shall be an independent contractor, and therefore, no party shall be entitled to any benefits applicable to any employee of the other
party. 

24

 

No
party is authorised to act as an agent for the other party for any purpose, and no party shall enter into any contract, warranty or representation as to any matter on behalf of the other party. 

16.    SCHEDULES  

A
reference to the terms of this Agreement shall be meant to include all Schedules. The following Schedules are incorporated and made part of this Agreement: 

        Schedule A.
Licensed Technology 

        Schedule B.
Licensed Patent Rights 

        Schedule C.
BI Intellectual Property 

        Schedule D.
Provision of Non-clinical BIWI1 

        Schedule E.
Major Terms of Technical Transfer Plan 

        Schedule F:
Development Plan 

        Schedule G.
Clinical Supply Agreement 

[Remainder
of page intentionally left blank] 

25

   
        IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed in triplicate by their duly authorised representatives. 

	Boehringer Ingelheim International GmbH ppa.	 	ImmunoGen, Inc.
	

 	

 	
 	

 
	

 Dr. K. Wilgenbus	

 Claudia Jesse	
 	

 Pauline Jen Ryan

26

  

 
 

Schedule A
  Licensed Technology    
  

        [ * ] (including [ * ] for [ * ] of
[ * ], [ * ] of [ * ] to [ * ],
[ * ] of [ * ], [ * ] of [ * ] to
[ * ], [ * ] of [ * ], and [ * ] of
[ * ] and [ * ] in biological material and in Drug Substance and Drug Product preparations). 

A-1

  

 
 

Schedule B
  Licensed Patent Rights    
  

[ * ]

	Attorney

Reference No.
 
	 	Country
	 	Appl. No.
	 	Filing Date
	 	Priority Date
	 	Patent No.
	 	Issue Date
	 	Exp. Date

	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	 	 	[ * ]	 	 	 	 
	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	
[ * ]	
 	
[ * ]	
 	
[ * ]	
 	
[ * ]	
 	
[ * ]	
 	
[ * ]	
 	
[ * ]	
 	
[ * ]
	 	 	[ * ]	 	 	 	 	 	 	 	 	 	 	 	 
	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	 	 	 
	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]

[ * ]

	Attorney

Reference No.
 
	 	Country
	 	Appl. No.
	 	Filing Date
	 	Priority Date
	 	Patent No.
	 	Issue Date
	 	Exp. Date

	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	 	 	[ * ]	 	 	 	 
	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	 	 	 

[ * ] (2)

	Attorney

Reference No.
 
	 	Country
	 	Appl. No.
	 	Filing Date
	 	Priority Date
	 	Patent No.
	 	Issue Date
	 	Exp. Date

	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	 	 	[ * ]	 	 	 	 

[ * ]

	Attorney

Reference No.
 
	 	Country
	 	Appl. No.
	 	Filing Date
	 	Priority Date
	 	Patent No.
	 	Issue Date
	 	Exp. Date

	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	 	 	 
	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	 	 	 

B-1

  

 
 

Schedule C
  BI Intellectual Property    
  

	BI Case No.
 
	 	Subject
	 	Expiry and

Status

Europe
	 	Expiry and

Status US
	 	File No. EP and

US
	 	Geographic

Coverage

	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]

C-1

  

 
 

Schedule D
  Provision of Non-clinical Drug Substance [g BIWI1]    
  

	Non-clinical Drug Substance

(g BIWI 1)
 
	 	2001
	 	2002
	 	2003
	 	2004

	[ * ]	 	[ * ]	 	 	 	 	 	 
	[ * ]	 	[ * ]	 	 	 	 	 	 
	[ * ]	 	[ * ]	 	[ * ]	 	 	 	 
	[ * ]	 	[ * ]	 	[ * ]	 	 	 	 
	[ * ]	 	 	 	 	 	[ * ]	 	[ * ]
	[ * ]	 	[ * ]	 	[ * ]	 	 	 	 
	[ * ]	 	[ * ]	 	[ * ]	 	 	 	 
	[ * ]	 	[ * ]	 	[ * ]	 	 	 	 
	[ * ]	 	[ * ]	 	 	 	 	 	 
	 	 	
	 	
	 	
	 	

	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 	 	
	 	
	 	
	 	

	TOTAL	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]

D-1

  

 
 

Schedule E
  Major Terms of Technical Transfer Plan    
  

        It is the intention of the parties that the Technical Transfer Plan referenced in Section 5.2 of this Agreement will be finalised by the parties as soon as
practicable and in any event no later than May 31, 2002. Both parties agree to negotiate such finalized terms in good faith, which shall be based on the transfer by ImmunoGen to BI of following
documentation, to the extent available: 

For Analysis purposes:  

        Documentation: 

	•
	[ * ]
and [ * ] for [ * ] of the
[ * ] covering [ * ] and [ * ] tests ([ * ] for
[ * ] including [ * ]/ [ * ])

	•
	[ * ]
and [ * ] for [ * ] covering tests
for [ * ], [ * ] and [ * ] (specifications for
[ * ] including [ * ]/ [ * ], i.e. [ * ], and
[ * ] products)

	•
	Justification
of the [ * ]

	•
	Justification
of [ * ] / [ * ] for Maytansine DM1

	•
	Preliminary
[ * ] data for analytical methods ([ * ]/
[ * ], [ * ], [ * ])

	•
	Analytical
results of all batches of [ * ]/ [ * ]

	•
	Preliminary
[ * ] data for Maytansine DM1 ([ * ] and
[ * ]) 

        Reference
substances: 

	•
	qualified
reference substances for [ * ] of the Maytansine DM1 synthesis (amount: at least
[ * ])

	•
	qualified
[ * ] of Maytansine DM1 (amount: at least [ * ])

	•
	qualified
[ * ] of [ * ] specified [ * ]
(in [ * ] and [ * ]) 

For Chemical Production Purposes:  

	•
	executed
batch records of [ * ] batches ([ * ])

	•
	analytical
methods for [ * ]

	•
	testing
specifications for [ * ] (see below)

	•
	samples
([ * ]) of each [ * ] (see below) 

        definition
of "[ * ]": 

	•
	[ * ]

	•
	[ * ]

	•
	[ * ]

	•
	[ * ]

	•
	[ * ]

	•
	[ * ]

	•
	[ * ] 

E-1

 

For Quality Testing purposes:  

        ImmunoGen will supply BI with substances that are necessary for BIWI1 quality testing (e.g. [ * ],
[ * ] etc.). 

        ImmunoGen
will supply BI with all required [ * ] and information on [ * ] of BIWI1. 

For Production purposes:  

	•
	Information
about safety precautions for all toxic substances, including ImmunoGen's for any steps that ImmunoGen takes for
[ * ] safety

	•
	Technical
requirements for the work with Maytansine and derivates for lab and scale up

	•
	[ * ]
([ * ]) [ * ] of all equipment used
in the BIWI 1 process

	•
	[ * ]
for each step of the manufacturing process ([ * ] and
[ * ])

	•
	Statistical
[ * ]/ [ * ] analysis regarding the executed production batches

	•
	Detailed
reports about different process times, reaction times, acceptable/necessary temperatures, additional information which is necessary e.g. working
with [ * ] ...

	•
	Detailed
report about necessary personal capacity for every production step

	•
	Copies
of the DMF and batch protocols from lots which were made at ImmunoGen

	•
	Risk
analysis of each production step (i.e. [ * ] [ * ] of each production step,
quality of the step when working in the prescribed process limits for example [ * ], [ * ],
[ * ], ...) 

General:  

        ImmunoGen will agree to [ * ] for the collaboration with BI throughout the [ * ]
process. To the extent practicable, ImmunoGen will attempt to include in the process employees (in the [ * ] and [ * ]
areas) who [ * ] the project with BI. 

        ImmunoGen
will agree, subject to [ * ], to host an [ * ] number of employees from BI at any time during the
Technical Transfer phase in order to [ * ] such employees [ * ] of the ImmunoGen equipment and fixed assets that are
necessary for the production of BIWI1. Such [ * ] sessions shall take place at ImmunoGen's facility at mutually convenient times and shall not exceed an aggregate
of [ * ] in duration. [ * ] shall [ * ] of [ * ]
and [ * ] of all such employees. ImmunoGen will also agree to let BI employees observe the production of at least [ * ]
Batch Runs of BIWI1. 

        ImmunoGen
will further agree to use [ * ] to make arrangements for BI employees to partake in a similar visit to ImmunoGen's contractor ChemSyn. 

        On
not less than [ * ] prior written notice from BI, ImmunoGen will also agree to [ * ] to the BI site for a
specific time not to exceed [ * ] (inclusive of [ * ]) in the aggregate, while the technology is being transferred.
BI will have the right to provide recommendations to ImmunoGen as to the [ * ] and [ * ] of such employees desired as well
as the [ * ] of such [ * ] employment. To the extent practicable, ImmunoGen will attempt to include in such
[ * ] employment those employees who have [ * ] the BI project. ImmunoGen and BI will agree to negotiate in good faith any
required extension of such temporary employment period. BI will agree to [ * ] ImmunoGen for [ * ] of its
[ * ] in connection with such temporary employment at an [ * ] of [ * ] for
[ * ] with no higher [ * ], and [ * ] for [ * ]
with a [ * ]. [ * ] and other [ * ], such as
[ * ], will also be [ * ] BI. 

        It
is the expectation of the parties that this Technical Transfer process will terminate as soon as BI Pharma produces at least [ * ] of BIWI1 which
comply with [ * ] and are suitable for [ * ] for [ * ]. 

E-2

  

 
 

Schedule F
  Development Plan for BIWI1    
  

Initial BIWI1 process development:  

Goal:    Develop a process for production of BIWI1 that can be  [ * ]  to [ * ] production of BIWI1 in the range of [ * ] per year to meet [ * ]  for [ * ] and [ * ]
studies. BIWI1 to be at a formulated concentration of [ * ]. 

Strategy:    [ * ] and [ * ] will be based on the process developed
during [ * ]  and  [ * ] , with increases in [ * ] to take account of
increasing [ * ] as well as   [ * ]. No significant changes to the process (eg., [ * ] ) are envisaged during this time-frame. 

	[ * ] and [ * ]	 	[ * ] (Completed)

[overall yield at this scale, [ * ]]
	

End [ * ] /

Beginning of [ * ]	
 	
Recommend process for [ * ] based on process data.
	
[ * ]	
 	

[ * ] ;

[ * ].

Drug Substance for [ * ] ( [ * ] , [ * ])
	
[ * ]	
 	
Evaluate process data. Compare to previous results. Investigate any anomalies and identify opportunities for process improvements.
	
[ * ] or [ * ]	
 	
 [ * ] at [ * ] Drug Substance for [ * ] work
	
[ * ]	
 	
Evaluate process data. Compare to previous results. Investigate any anomalies and identify opportunities for process improvements.
	
[ * ]	
 	

[ * ] 
	
[ * ] to
 [ * ]	
 	

[ * ] at [ * ]
	
[ * ]	
 	

Evaluate process data ([ * ]). Compare to previous results. Investigate any anomalies and identify opportunities for process improvements.
	
[ * ] to
 [ * ]	
 	

[ * ]
	
[ * ]	
 	

Evaluate process data ([ * ]). Compare to previous results. Investigate any anomalies and identify opportunities for process improvements.
	
[ * ]	
 	

[ * ]

ASSUMPTIONS:  

	(a)
	Development
plan will yield [ * ] of BIWI1 for [ * ] use (though some [ * ]  of [ * ] material may be used for  [ * ] toxicology work), assuming yields at  [ * ]  are
similar to those obtained at  [ * ].

	(b)
	[ * ] development plan is successfully executed.

	(c)
	The
above time-frames are for manufacture of bulk BIWI1, and do not include [ * ].

	(d)
	Assumes
that key [ * ] and [ * ]  are available and delivered in a timely manner. 

F-1

 

 
 

Plan for the development of Ansamitocin P3 production and DM1 production    
  

Supplies of DM1 for 2001 and 2002  

Purchase [ * ]. [ * ]. 

Development Plan for Ansamitocin P3 production:  

[ * ] under way since [ * ]  , at  [ * ]. This is an ongoing development program to
develop a [ * ] for commercialization. However, an [ * ] was
selected for manufacture of [ * ] for  [ * ]. 

[ * ] selected for [ * ]  production in [ * ]. 

[ * ] using the [ * ] ,
including  [ * ] development was [ * ]  in  [ * ] , at
[ * ]. Certain aspects of this development program are also under way at [ * ] with the [ * ].
 

[ * ]: Transfer of [ * ]  process to  [ * ]. 

[ * ] to [ * ] : ImmunoGen
develops downstream processing for ansamitocin isolation. 

[ * ]: Transfer [ * ] from
ImmunoGen to [ * ]. 

[ * ]: [ * ] manufacture of ansamitocin from  [ * ] at [ * ]. 

[ * ]: [ * ]  of [ * ] ready for shipment. 

[ * ]: [ * ]  manufactures [ * ] in  [ * ]
. 

[ * ]            [ * ] begins to produce  [ * ] . 

After
the initial process is implemented, efforts will continue in the area of  [ * ] as well
as [ * ],  [ * ]  and [ * ] of  [ * ]
. 

Development Plan for DM1 production  

[ * ]:    Ensure that [ * ]  is ready to [ * ] manufacture of
DM1 for ImmunoGen. Currently,  [ * ] estimates that [ * ] DM1
is [ * ] after [ * ] of   [ * ]. Some development work in [ * ]  may  [ * ] the time-frame 

Starting
in the [ * ]: Produce DM1 from [ * ]  at [ * ] on a 
[ * ]  basis of [ * ]. 

[ * ] supply from [ * ] from
the [ * ] of [ * ] will be
sufficient to allow process development work to prepare for [ * ] of DM1 

[ * ]:    DM1 obtained from [ * ]  from the [ * ] is used in
the [ * ] of BIWI1. May require [ * ] , as appropriate. 

F-2

 
 

Schedule G
  Clinical Supply Agreement    
  

 
 
 

CLINICAL SUPPLY AGREEMENT    
  

This
CLINICAL SUPPLY AGREEMENT (this "Agreement") is entered into as of November 27, 2001 (the "Effective Date") by and between ImmunoGen, Inc., a Massachusetts corporation having its
principal office at 128 Sidney Street, Cambridge, Massachusetts 02139, USA ("ImmunoGen"), and Boehringer Ingelheim Pharma KG, a company organized under the laws of Germany having its principal office
at Binger Strasse 173, 55218 Ingelheim am Rhein, Germany ("BI Pharma"). ImmunoGen and BI Pharma are sometimes referred to individually herein as a "Party" and collectively as the "Parties." 

        WHEREAS,
Boehringer Ingelheim International GmbH at Binger Strasse 173, 55218 Ingelheim am Rhein, Germany ("BI") and ImmunoGen have contemporaneously entered into a Development and
License Agreement as of the Effective Date (the "License Agreement"), and BI Pharma is an Affiliate of BI; and 

        WHEREAS,
the License Agreement provides the basis for the manufacture and supply of Drug Substance for non-clinical use to BI or as directed by BI under the License Agreement
and, moreover, states that ImmunoGen and BI Pharma shall enter or have entered into contemporaneously a supply
agreement for the manufacture and supply of Drug Product for clinical use (this "Agreement") attached to that License Agreement as Schedule G;
and 

        WHEREAS,
the Parties are in agreement that the definitions used in the License Agreement and this Agreement shall have the same meaning, force and effect, unless expressly otherwise
provided for in this Agreement; and 

        WHEREAS,
ImmunoGen has agreed to supply BI Pharma or as directed by BI Pharma with such quantities of Drug Product as BI Pharma may reasonably request subject to the terms and conditions
set forth herein; 

        NOW,
THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Parties agree
as follows: 

1.    DEFINITIONS  

        Whenever used in this Agreement with an initial capital letter, the respective terms shall have the meanings used in the License Agreement and shall be
incorporated by reference herein and the terms defined in this Section 1 shall have the meanings specified hereinafter. 

        1.1  "BIWA4" means unconjugated BIWA4 monoclonal antibody. 

        1.2  "Drug Substance Batch" means a specific quantity of the Drug Substance that is intended to be of uniform character and
quality and is produced during the same Batch Run. 

        1.3  "Drug Product Batch" means a specific quantity of the Drug Product that is intended to be of uniform character and
quality and is produced during the same aseptic filling campaign. 

        1.4  "Batch Run" shall mean the production and purification process performed by ImmunoGen to generate a Batch of Drug
Substance pursuant to this Agreement. 

        1.5  "Calendar Quarter" means each period of three consecutive calendar months ending on March 31, June 30,
September 30 or December 31. 

        1.6  "Calendar Year" means each successive period of twelve months commencing on January 1 and ending on
December 31. 

        1.7  "Certificate of Analysis" means a document, signed by an authorized representative of ImmunoGen, describing
specifications for, and testing methods applied to Drug Product or Drug 

G-2

 

Substance, and the results thereof. A template of the Certificate of Analysis is attached hereto as Schedule I. 

        1.8  Direct Cost" shall mean with respect to any Drug Product or Drug Substance, the fully-burdened costs of producing
(including the costs associated with product testing and release activities) and packaging of such Drug Product or Drug Substance, including the sum of the following components: (a) the direct
costs, including direct labor and materials, of producing and packaging such Drug Product or Drug Substance; (b) all manufacturing overhead costs incurred by ImmunoGen attributable to the cost
of goods under the foregoing clause (a), including supervisory services, occupancy costs, purchasing, human resources, payroll, information system and accounting which are allocable to company
departments based on space occupied or headcount or another activity-based method; (c) any other costs borne by ImmunoGen for the transport, customs clearance, duty, insurance and/or storage of
Drug Product or Drug Substance; and (d) general and administrative costs which are allocable to company departments based on space occupied or headcount or another activity-based method. In no
event shall the indirect manufacturing cost allocated to BI Pharma exceed $175,000 per Batch Run. Notwithstanding the foregoing, Direct Cost of Drug Product or Drug Substance shall not include
(i) the cost of purchasing any Dedicated Equipment to the extent reimbursed by BI Pharma pursuant to Section 5.5 of this Agreement, (ii) the cost of failed batches other than
pursuant to Section 6.4 of this Agreement, (iii) the cost of DM1 Inventory acquired at BI Pharma's expense pursuant to Section 6.8 of this Agreement, or (iv) any indirect
costs allocable to batches produced for third parties in the Facility. If BI or BI Pharma as the case may be can reasonably demonstrate to ImmunoGen that any equivalent materials, components or
equipment used for the production of Drug Substance and/or Drug Product of the same quality, quantity and timing can be purchased at a lower price than ImmunoGen's Direct Cost and such materials or
components, or that equipment can be supplied on a reasonably consistent and reliable basis, then ImmunoGen shall accept such lower price for the calculation of the Direct Cost. 

        1.9  "Draft Specifications" means the preliminary written specifications established for the characteristics, and quality as
well as quality control testing procedures for Drug Product or Drug Substance as the case may be, as developed and mutually approved by the Parties in accordance with the License Agreement, and
attached hereto as Schedule A. Draft Specifications shall dictate the manufacture of Drug Product until such time as the Final Specifications (as
hereinafter defined) are agreed to by the Parties in accordance with Section 3.2. 

        1.10 "Drug Product" means Drug Substance, manufactured under cGMP in the final concentration for clinical use, aseptically
filled in unlabeled, primary packaging material. 

        1.11 "Drug Substance" means bulk BIWI1 as defined in the License Agreement. 

        1.12 "Dedicated Equipment" means any equipment or machinery exclusively used by ImmunoGen in the manufacturing of Drug
Substance. 

        1.13 "Facility" means ImmunoGen's manufacturing facility used for manufacture of Drug Substance located at 333 Providence
Highway, Norwood, Massachusetts USA 02062 and all equipment contained therein. 

        1.14 "Good Manufacturing Practices" or "cGMP" means the current good manufacturing practices applicable to the manufacturing
of a Drug Product under Title 21 of the United States Code of Federal Regulations as amended from time to time. 

        1.15 "Final Specifications" means the final written specifications established for the characteristics, quality and quality
control testing procedures for Drug Substance or Drug Product, as developed and approved by the Parties in accordance with Section 3.2 of this Agreement. 

G-3

 

        1.16 "Manufacturing Process" means any and all processes (or a singular step in any process) used or planned to be used by
ImmunoGen for the manufacturing of Drug Substance and Drug Product as described in Master Batch Records. 

        1.17 "Manufacturing Documentation" shall mean all executed batch records and all deviation reports and investigation reports
associated with each individual Batch Run. 

        1.18 "Master Batch Record" means a written description of the Manufacturing Process for Drug Substance or Drug Product, which
shall be approved by BI Pharma prior to start of production of the first cGMP Drug Substance or Drug Product Batch. All such batch records shall include all technical requirements and specifications
with regard to the manufacturing methods, packaging process, and storage methods and procedures, as applicable. 

        1.19 "Subcontractor" means any independent third party or entity contractually engaged to act on behalf of ImmunoGen in order
to perform the Manufacturing Process or any quality control steps for Drug Substance or Drug Product. 

        1.20 "Transfer Price" shall mean the price of any Drug Product to be invoiced by ImmunoGen and payable by BI Pharma upon
delivery of such Drug Product to BI Pharma, which shall be determined in accordance with Section 7.1 hereof. 

        1.21 "Other Definitions" shall have the meaning as defined in the respective Sections enumerated below. 

        "Shipment
Order", see Section 3.4 

        "Key
Materials Supply Agreements", see Section 3.6 

        "Drug
Product Forecast", see Section 4.2 

        "Purchase
Order", see Section 4.3 

        "Laboratory",
see Section 6.1.3 

        "Review",
see Section 6.1.2 

        "DM1
Inventory", see Section 6.8 

        "Term",
see Section 9.1 

        "Event
of Default", see Section 0 

        "Competent
Authority", see Section 11.3 

        "Indemnitor",
see Section 12.1.3 

        "Indemnitee",
see Section 12.1.3 

2.    SCOPE OF AGREEMENT  

        2.1  Scope. Any reference to a defined term or concept, including but not limited to those relating to the supply of Drug
Product, financial terms, intellectual property, indemnification, termination or governance, not specifically contained in or otherwise addressed by this Agreement shall be governed by the terms and
conditions as set forth in the License Agreement and, as such, any and all terms and conditions of the License Agreement shall be incorporated by reference herein. 

        2.2  Objective. The overall objective of this Agreement is to govern the terms and conditions pursuant to which ImmunoGen will
produce for (or will have produced for as permitted herein) and supply to BI Pharma or as directed by BI Pharma, Drug Product for Phase I and non-pivotal Phase IIa 

G-4

 

human clinical trials. The production and supply of Drug Substance for non-clinical use is governed by the License Agreement. 

3.    SUPPLY AND SPECIFICATIONS  

        3.1  Supply. ImmunoGen is obliged to supply BI Pharma with certain quantities of Drug Product in order for BI Pharma to
conduct Phase I Trials and non-pivotal Phase IIa Trials. The minimum quantities of clinical Drug Product to be supplied to BI Pharma by ImmunoGen in each respective Calendar Year during
the Term of this Agreement is attached hereto as Schedule G. It is the understanding of ImmunoGen and BI Pharma that ImmunoGen shall not be
obliged to supply BI Pharma with quantities in excess of five percent (5%) of the amounts of Drug Product in each respective Calendar Year as listed in  Schedule G attached to this Agreement,
provided that ImmunoGen shall use all reasonable efforts to fulfill any such request. ImmunoGen shall
produce Drug Product in a series of Batch Runs, the exact number and size of which shall be determined by the Parties. The Parties acknowledge that the number, size and/or yield of Batch Runs are
subject to change due to numerous factors, including
but not limited to production and purification processes, recruitment of patients to clinical trials and the number of and dosing schedules chosen for human clinical trials. 

        3.2  Drug Substance and Drug Product Specifications. Draft Specifications for Drug Substance and Drug Product as provided by
BI Pharma are attached hereto as Schedule A. The Parties acknowledge that these Draft Specifications are subject to change with the collection of
Batch Run manufacturing data. Final Specifications have to be defined mutually by the Parties prior to manufacture of the first clinical batch. ImmunoGen shall not make any changes to the Final
Specifications and the Master Batch Records, without the prior written permission of BI Pharma; in the event that ImmunoGen has made any such unauthorised changes, ImmunoGen shall be held solely
liable for the consequences of such changes and for any claim for damages or indemnification arising therefrom. Upon the determination of the Final Specifications, the Draft Specifications will no
longer be applicable to the manufacture of Drug Substance and Drug Product and shall be replaced in full by the terms of the Final Specifications. 

        3.3  Manufacturing Process and Master Batch Records. ImmunoGen will provide BI Pharma with Master Batch Records describing the
Manufacturing Process for Drug Product as well as for Drug Substance. ImmunoGen shall supply BI Pharma with all required written information, including but not limited to standard operating
procedures, describing quality control procedures for testing of Drug Substance and Drug Product. The Master Batch Records will be agreed upon by the Parties prior to manufacturing of the first cGMP
batch. Any change to the Master Batch Records requires prior written approval by BI Pharma. ImmunoGen will provide copies of all Manufacturing Documentation to BI Pharma. 

        3.4  Provision of BIWA4. BI Pharma shall deliver the necessary quantities of BIWA4, at BI Pharma's sole cost, for a Batch Run
no less than [ * ] days prior to the scheduled initiation of the Batch Run. The Parties acknowledge that the
necessary quantity of BIWA4 is subject to change and is dependent on the number, size and/or yield of Batch Runs. ImmunoGen shall not be responsible for any delay caused by BI Pharma's failure to
deliver such BIWA4 as contemplated by this Section 3.4. BI Pharma shall provide or arrange to provide ImmunoGen free of charge with such quantities of BIWA4 as shall be necessary according to
the Master Batch Records for the manufacture of Drug Product for BI Pharma. ImmunoGen shall use the BIWA4 exclusively for the manufacturing of Drug Product for BI Pharma. ImmunoGen shall store BIWA4
in controlled areas and in accordance with the conditions specified by BI Pharma. ImmunoGen shall issue a written request for BIWA4 to BI Pharma (a "Shipment Order") including, but not limited to,
amount and delivery date not later than [ * ] prior to the scheduled initiation of the Batch Run. 

G-5

 

        3.5  Excipients and Other Components. ImmunoGen shall purchase  [ * ] all excipients (pharmacopoeial grade), and other items of any nature whatsoever that
ImmunoGen may use or
have used in manufacturing the Drug Product, other than BIWA4. [ * ] the  [ * ] for ensuring that all  
[ * ] used in the manufacture of Drug Product, comply with the Draft Specifications and Final Specifications and
all applicable laws and regulations. ImmunoGen shall test and release all materials for identity and quality in accordance with the Draft Specifications and Final Specifications prior to using the
same. All right,
title and interest in and to such items, and in and to all work-in-process incorporating such items, shall remain the sole property of ImmunoGen. 

        3.6  Key Materials. ImmunoGen has entered into agreements for the supply of ansamitocin P3 and DM1 ("the Key Materials Supply
Agreements") and believes, to the best of its knowledge, that the supply of ansamitocin P3 and DM1 under the Key Materials Supply Agreements, as in effect on the Effective Date, is sufficient to
satisfy BI's requirements for Drug Product under Section 3.1 of the Supply Agreement. A list of the Key Materials Supply Agreements is attached hereto as  Schedule E. 

4.    FORECASTS AND PURCHASE ORDERS  

        4.1  Initial Supply Forecast. The minimum quantities of clinical Drug Product to be supplied to BI Pharma by ImmunoGen during
the Term of this Agreement is attached as an initial non-binding forecast for Drug Product in Schedule G (provision of clinical Drug
Product). In Schedule G the total quantity of Drug Product that BI Pharma expects to order from ImmunoGen based upon ImmunoGen's current
manufacturing capacity is listed beginning with the first Calendar Year after the Effective Date. 

        4.2  Drug Product Forecasts. BI Pharma shall use its best efforts to submit to ImmunoGen within thirty (30) days of the
Effective Date and thereafter at least three (3) calendar months prior to the start of each Calendar Quarter, a rolling written forecast of the quantities of Drug Product estimated to be
required for the following four Calendar Quarters ("Drug Product Forecast"). In the Drug Product Forecast, BI Pharma shall include a breakdown of the total quantity of Drug Product by Calendar
Quarters. The Parties acknowledge that factors including, but not limited to, number of human clinical studies conducted, clinical study enrollment and stability of Drug Product might affect the
accuracy of such Drug Product Forecasts. BI Pharma therefore will amend from time to time the Drug Product Forecast so as to account for such variables. 

        4.3  Delivery of Purchase Order; Contents. Together with each Drug Product Forecast, BI Pharma shall deliver to ImmunoGen, in
writing, a binding purchase order ("Purchase Order") for Drug Product for the second Calendar Quarter (as the first Calendar Quarter will already be covered by the initial Purchase Order covering the
first and second Calendar Quarters). Subsequent Purchase Orders shall equal the Drug Product Forecast for the second Calendar Quarter of the accompanying forecast. Each Purchase Order shall specify:
(i) the total quantity of Drug Product; (ii) a reference to the actual Final Specification and the Master Batch Records; (iii) the requested location for delivery;
(iv) time of delivery; and (v) the carrier and/or manner of shipment that ImmunoGen should use in delivering the Drug Product. 

        4.4  Governing Terms. For ordering, the Parties shall use their standard forms (see  Schedule F: Purchase Order BI Pharma), however all orders shall be subject to
the provisions of this Agreement and shall not be subject to any
inconsistent terms and conditions contained on any Purchase Order or Shipment Order, except insofar as any such document or request establishes: (a) the quantity of Drug Product to be shipped;
(b) the delivery date; (c) the requested location for delivery; or (d) the carrier and/or manner of shipment. 

        4.5  Penalty for Failure to Supply. In the event that, over a given Calendar Year, ImmunoGen fails to supply BI Pharma with at
least [ * ] of the lesser amount of  [ * ] specified in the [ * ]
for that [ * ] or the [ * ]
of [ * ] specified in Schedule G for that  [ * ] and such failure is not
attributable to a 

G-6

 

contingency set forth in Section 13.1 or to a breach by BI Pharma or BI of this Agreement, then, subject to the final sentence of this Section 4.5, ImmunoGen shall forgo certain
milestone payments [ * ] under the  [ * ] as follows. If such  [ * ] to
[ * ] occurs  [ * ] the [ * ] of  [ * ]
, then ImmunoGen shall forgo the  [ * ] milestone payments  [ * ] and [ * ]
 to
Section 3.2 of the [ * ]. If such  [ * ] to [ * ] occurs  [ * ] the [ * ] of
[ * ], then ImmunoGen shall forgo the  [ * ] milestone payments  [ * ] and
[ * ] pursuant to
Section 3.2 of the [ * ]. The foregoing notwithstanding, ImmunoGen shall have  [ * ] from the end of the  [ * ] to [ * ] such  [ * ] and not forgo any milestone payments. 

        4.6  Notices. All notices to ImmunoGen under this Section 4 shall be delivered to ImmunoGen to the attention of  [ * ] at 128 Sidney Street, Cambridge,
Massachusetts USA 02139 or to such other person and location as ImmunoGen
may specify to BI Pharma in writing from time to time. 

5.    PRODUCTION  

        5.1  Batch Runs. All production and supply by ImmunoGen of Drug Product under this Agreement shall be denominated in terms of
Batch Runs. ImmunoGen will review each Drug Product Forecast and determine [ * ] the exact number and size of the
Batch Runs necessary to fulfill each Purchase Order. The Parties acknowledge that the number, size and/or yield of Batch Runs are subject to change due to numerous factors, including but not limited
to production and purification processes. [ * ] to  [ * ] and [ * ] the 
[ * ] for[ * ] to  [ * ] for [ * ] of  [ * ] (for details, see  [ * ] Section [ * ]). The
Parties agree that all changes to the Manufacturing Process are subject to a change control procedure and have to be finally agreed upon by BI Pharma. ImmunoGen shall complete in accordance with the
requirements of cGMP a Manufacturing Documentation and a Certificate of Analysis for every Drug Substance Batch and Drug Product Batch. ImmunoGen shall provide copies of this documentation and shall
maintain all documentation pertaining to the Drug Product for at least [ * ] of the date of final release by BI
Pharma of the Drug Product. 

        5.2  Specifications. All Drug Product supplied to BI Pharma hereunder (i) will comply with all applicable Draft
Specifications or Final Specifications at the time of manufacture and (ii) will have been manufactured in accordance with the Master Batch Records and cGMP. 

        5.3  Facility. ImmunoGen shall conduct all manufacturing of the Drug Substance at the Facility and shall maintain at the
Facility all equipment, Dedicated Equipment, components and other items used to manufacture Drug Substance. ImmunoGen (i) shall notify BI Pharma in writing, not less than  [ * ] prior to
any proposed, foreseeable change in the location or status of the Facility and (ii) shall
notify BI Pharma in writing as soon as possible of any unforeseeable change in the location or status of the Facility and (iii) shall be responsible for obtaining, at its own expense, any
necessary regulatory approvals in connection with any such change and BI Pharma's agreement thereto. [ * ] to  [ * ] with the
[ * ] to  [ * ] at the Facility. Any  [ * ] in the 
[ * ] of the  [ * ], which shall not be unreasonably withheld. 

        5.4  Subcontractors. Notwithstanding the following provision, ImmunoGen shall not be allowed to engage any Subcontractor in
the production and control of the Drug Product without the prior written agreement of BI Pharma. The list of presently agreed-to Subcontractors is attached hereto as  Schedule H. ImmunoGen bears
full responsibility regarding quality, amount, and timing of supplies of Drug Product. ImmunoGen (i) shall
notify BI Pharma in writing, not less than six (6) months prior to any proposed, foreseeable change in the Subcontractor and (ii) shall notify BI Pharma in writing as soon as possible of
any unforeseeable change in the Subcontractor. However, in the case of a change in Subcontractor, start of manufacturing or control activities of Drug Product shall require the prior written
permission of BI Pharma. ImmunoGen hereby assures that BI Pharma has the right to audit each of ImmunoGen?s Subcontractors, to be present during processing, if feasible, and that the
Subcontractor is willing to enter into a separate quality agreement with ImmunoGen at BI Pharma?s option. 

G-7

 

        5.5  Dedicated Equipment. ImmunoGen shall supply, at its own expense, all equipment required for the purpose of manufacturing
the Drug Substance. Notwithstanding the foregoing, if during the Term of this Agreement, the Parties determine in good faith negotiations that it is necessary or advisable to purchase Dedicated
Equipment for ImmunoGen to perform any of its obligations to manufacture Drug Substance under this Agreement, then ImmunoGen shall provide BI Pharma with written notice within a reasonable time of
such determination, along with the estimated price for such purchase and quality parameters for such Dedicated Equipment, in order to achieve BI Pharma's written approval of the same. The Parties
shall evaluate jointly the costs of such Dedicated Equipment to determine whether the price to be paid for such Dedicated Equipment is reasonable to the Parties and whether such Dedicated Equipment
could be procured at a lower cost. ImmunoGen shall provide BI Pharma with a likely list of Dedicated Equipment to define an upper limit of Dedicated Equipment costs, which will be necessary during the
production of Drug Product (see Schedule B). Subject to the foregoing, promptly after the consummation of such purchase on behalf of BI Pharma,
ImmunoGen shall provide BI Pharma with a copy of the invoice or invoices reflecting such purchase(s), and BI Pharma shall reimburse ImmunoGen for the purchase of all such agreed Dedicated Equipment
hereunder within thirty (30) days of its receipt of such invoices from ImmunoGen. All such Dedicated Equipment shall be owned by BI Pharma, shall be maintained, decontaminated and cleaned by
ImmunoGen as long as ImmunoGen has possession thereof, and shall be used by ImmunoGen solely for the benefit of BI
Pharma. The Parties hereby agree that any costs that are incurred by ImmunoGen and are reimbursed by BI Pharma under this Section 5.5 shall not be included within the calculation of any Direct
Cost under this Agreement. Upon any termination of this Agreement, ImmunoGen shall permit BI Pharma to remove all such Dedicated Equipment from its Facility at BI Pharma's sole cost and expense,
provided, that any reimbursement due by BI Pharma for such Dedicated Equipment has been fully paid to ImmunoGen. 

        5.6  Maintenance of Facility. ImmunoGen shall maintain, at its own expense, the Facility, (including, without limitation the
equipment and the Dedicated Equipment) in a state of repair, cleanliness and operating efficiency consistent with the requirements of the Draft Specifications and Final Specifications respectively,
cGMP and other applicable requirements. 

6.    DELIVERY, TESTING AND ACCEPTANCE  

        6.1  Pre-Delivery Testing.

        6.1.1.    ImmunoGen Responsibilities.    Prior to delivery to BI Pharma, ImmunoGen shall test, or cause to be tested,
a representative sample of each Drug Product Batch (or components as applicable) to demonstrate that such Drug Product Batch complies with the applicable specifications (manufacturer's release). For
each Drug Product Batch to be delivered to BI Pharma or to a recipient designated by BI Pharma, ImmunoGen shall prepare and submit a representative sample of such Drug Product Batch, and a Certificate
of Analysis that identifies the items tested, the applicable specifications and test results. The present format and required content of the Certificate of Analysis is attached hereto as  Schedule I. Any changes thereto shall be agreed upon by the Parties. ImmunoGen will also submit a copy of the Manufacturing Documentation.
ImmunoGen shall provide raw data upon reasonable request by BI Pharma. 

        6.1.2.    BI Pharma Responsibilities.    Prior to delivery to BI Pharma, BI Pharma shall determine whether the Drug
Product conforms to applicable specifications for use in human clinical trials (the "Review"). BI Pharma may conduct a Review by: (i) reviewing the Certificate of Analysis and the Manufacturing
Documentation and such other documents, if any, as BI Pharma may request; and (ii) conducting acceptance testing of a representative sample of the Drug Product Batch. BI Pharma shall conduct
its Review within [ * ] of the receipt of a representative sample of the Drug Product Batch including
Manufacturing Documentation of Drug Substance, [ * ] that  [ * ] have a [ * ]
of  [ * ] for [ * ] after  [ * ] of [ * ]
and
[ * ] after [ * ] of  [ * ] the [ * ]
. 

G-8

 

        6.1.3.    Specification Dispute Resolution.    In case of any disagreement between the Parties as to whether a Drug
Product conformed with applicable Draft Specifications or Final Specifications, a representative sample of the disputed Drug Product shall be submitted for tests and final determination of whether the
Drug Product conformed with such applicable specifications to an independent testing organization mutually agreed upon by the Parties (the "Laboratory"). The Laboratory must meet current Good
Laboratory Practices as defined by the FDA from time to time, and the appointment of such Laboratory shall not be unreasonably withheld or delayed by either Party. Such Laboratory shall use the test
methods contained in the applicable specifications. The determination of such Laboratory with respect to all or part of the Drug Product shall be final and binding on the Parties. The fees and
expenses of the Laboratory incurred in making such determination shall be paid by the Party against whom the determination is made. 

        6.2  Notification. Within [ * ] of the
completion of the Review, BI Pharma shall notify ImmunoGen in writing whether the Drug Product conforms to Final Specifications. 

        6.3  Defective Product; Inspection and Rejection; Shortages. In the event that any Drug Product Batch after delivery to BI
Pharma is detected to fail to comply with the Final Specifications, ImmunoGen shall, at its own cost (a) deliver replacement quantities of such Drug Product to BI Pharma or make up the
shortage, as the case may be, [ * ]; or (b) if replacement is not possible despite ImmunoGen's  [ * ], at BI Pharma's discretion,
either refund or credit BI Pharma's account for the amount paid for such Drug
Product. ImmunoGen may analyze any Drug Product rejected for nonconformity. The foregoing does not apply if the cause of the defect is beyond the reasonable control of ImmunoGen. Moreover, the
foregoing applies only if nonconformance is detected prior to the expiry date of the Drug Product Batch. BI Pharma shall bear the cost and responsibility for the replacement of defective product
attributable to instability until such time as the Parties determine stability over six months from data generated with the first cGMP Drug Product Batch. Any dispute regarding defective product under
this Section 6.3 shall be resolved in the same manner as provided for in Section 6.1.3. 

        6.4  Failed Batches. ImmunoGen shall bear the responsibility for a failed Batch Run if such failure is attributable to the
negligence or misconduct of ImmunoGen. The foregoing notwithstanding, the Parties acknowledge that there may be Batch Run failures not attributable to either Party. Cost sharing of such failed batches
shall take place according to the table in Schedule C, in which the success rate improves according to the number of batches produced. 

        6.5  Shipment. Upon receipt of written notice from BI Pharma, ImmunoGen shall deliver to BI Pharma or as directed by BI Pharma
the respective Drug Product on the date provided for in the respective Purchase Order. Drug Product delivered pursuant to the terms of this Agreement shall be suitably packed and marked for shipment
according to BI Pharma's Purchase Order. Delivery terms shall be DDP location in EU as determined by BI Pharma in the respective Purchase Order or CIP Ridgefield (INCO terms 2000) at BI Pharma's
option. [ * ] to the  [ * ] be [ * ] to  
[ * ] upon [ * ] of  [ * ]. The Parties shall agree on a preferred carrier, packaging material, and
detailed insurance conditions.
 

        6.6  Final Release. BI Pharma shall be responsible for the release of Drug Product for use in clinical trials (final release). 

        6.7  Notices. All notices to ImmunoGen under this Section 6 shall be delivered to ImmunoGen to the attention of  [ * ] at 333 Providence Highway,
Norwood, Massachusetts USA 02062 or to such other person and location as
ImmunoGen may specify to BI Pharma in writing from time to time. 

        6.8  Inventory. In an effort to mitigate the risk of having the supply of Drug Product affected by the unavailability of
ansamitocin P3, BI Pharma and ImmunoGen hereby agree to use reasonable commercial efforts during the Term of this Agreement to acquire and maintain an inventory of DM1 in excess of the amounts
required to manufacture the Drug Product listed on Schedule E of the License 

G-9

 

Agreement, as it becomes available and to the extent it is not otherwise committed or allocated to any other party and can be procured under commercially reasonable terms and conditions (the "DM1
Inventory"). In connection therewith, ImmunoGen shall provide reasonable written notice to BI of the availability of such DM1 Inventory and the cost of obtaining such DM1 Inventory as well as the
other material terms (if any) of such purchase and BI Pharma shall indicate to ImmunoGen whether it wishes ImmunoGen to obtain such DM1 Inventory on such terms. Subject to the foregoing, all costs
associated with obtaining the amount of agreed upon DM1 Inventory shall be borne by BI Pharma. Upon any termination of this Agreement, ImmunoGen shall permit BI Pharma to remove all such DM1 Inventory
from its Facility at BI Pharma's sole cost and expense, provided, that any reimbursement due by BI Pharma for such DM1 Inventory has been fully paid to ImmunoGen. 

7.    PRICE AND PAYMENT  

        7.1  Transfer Price for Product. All Drug Product supplied to BI Pharma or a third party designated by BI Pharma under this
Agreement shall be supplied to BI Pharma at a Transfer Price equal to [ * ] of ImmunoGen's  [ * ] of such 
[ * ] in
accordance with Section [ * ] hereof. 

        7.2  Invoicing and Timing. The payment will be made thirty (30) days upon written notice of receipt of the Drug Product
by BI Pharma and after receipt by BI Pharma of the respective invoice, detailing VAT separately if any. The invoice or an attachment thereto shall contain the agreed upon breakdown of Direct Costs as
described in Schedule D. In case of failed batches that BI Pharma is obligated to pay for pursuant to  Schedule C, payment shall be made within
thirty (30) days of receipt of such invoice. Any invoices which remain unpaid more than thirty
(30) days beyond the scheduled payment due date may be subjected to an interest charge at a rate of 1% per month (12% per annum), calculated from the scheduled payment due date forward. 

        7.3  Notices. All notices to BI Pharma under this Section 7 shall be delivered to BI Pharma to the attention of
Grp.Contr.F+E+M Pharma D, att.: [ * ] at Birkendorfer Str. 65, 88397 Biberach, Germany,
or to such other person and location as BI Pharma may specify to ImmunoGen in writing from time to time. 

8.    TITLE AND AUDIT RIGHTS  

        8.1  BI Pharma Audit Rights.

        8.1.1.    Audit of Facility.    ImmunoGen agrees that BI Pharma and its agents shall have the right, upon reasonable
prior notice to ImmunoGen, to inspect the Facility and audit ImmunoGen's quality control system and be present during Batch Runs during normal business hours in order to ascertain compliance by
ImmunoGen with the terms of this Agreement, including, but not limited to, inspection of (a) the materials used in the manufacture of the Drug Product, (b) the holding facilities for
such materials, (c) the equipment used to manufacture the Drug Product, (d) the quality control procedures and (e) all records relating to such manufacturing, quality control and
Facility. Any information disclosed in writing, orally or by inspection of tangible objects shall be considered ImmunoGen's Confidential Information and protected as such by BI Pharma and its agents
pursuant to the terms of the License Agreement. ImmunoGen agrees to take adequate and reasonable corrective actions of audit findings of BI Pharma and will issue a formal written response to the audit
report. 

        8.1.2.    Audit of Subcontractors.    ImmunoGen shall insure that Subcontractors' facilities can be inspected by BI
Pharma for audit purposes in the same manner as described in Section 8.1.1 above. 

G-10

  

        8.1.3.    Audit of Total Cost.    ImmunoGen shall keep complete and accurate records of its Total Cost of Drug Product
supplied under this Agreement in sufficient detail to allow such Total Cost to be determined accurately. BI Pharma shall have the right, during the Term of this Agreement  [ * ], to appoint an
independent certified public accountant reasonably acceptable to ImmunoGen to inspect the
relevant records of ImmunoGen to verify its statements of Total Cost of Drug Product. ImmunoGen shall make its records available for inspection by such independent certified public accountant during
regular business hours at such place or places where such records are customarily kept, upon reasonable notice from BI Pharma, solely to verify the accuracy of its statements of Total Cost of Drug
Product. Such inspection right shall not be exercised more than [ * ] during any  [ * ] period. BI Pharma agrees to hold in strict
confidence all information concerning ImmunoGen's costs, and all
information learned in the course of any audit or inspection, except to the extent necessary for BI Pharma to reveal such information in order to enforce its rights under this Agreement or if
disclosure is required by law, regulation or judicial order. The results of each inspection, if any, shall be binding on both Parties. BI Pharma shall pay for such inspections, except that, in the
event an inspection reveals an overcharge to BI Pharma of greater than [ * ], ImmunoGen shall pay for such
inspection. 

        8.2    Government Inspections.    ImmunoGen, in accordance with applicable laws and
regulations, shall permit representatives of any regulatory agency having jurisdiction over the manufacture and/or marketing of the Drug Substance or the Drug Product, including the FDA and the EMEA,
but not limited to the same, to inspect its Facility in conjunction with the manufacture, quality control, registration, storage, handling and shipping of the Drug Product. ImmunoGen shall promptly
advise BI Pharma if ImmunoGen receives a notice of an impending inspection or if an authorized agent of the FDA or other governmental agency visits any of ImmunoGen's facilities including the Facility
concerning the Drug Product. ImmunoGen shall furnish to BI Pharma non-confidential copies of any report, including any FDA Form 483 notices (or comparable notices of other
agencies), regulatory letters or similar documents received from such agency and the application of such report to Drug Product, if any, within  [ * ] of ImmunoGen's receipt of such report.

9.    TERM AND TERMINATION  

        9.1    Term.    This Agreement shall become effective on the Effective Date and shall continue
in full force and effect until the earlier of the conclusion of Phase I Trials and non-pivotal Phase IIa Trials or the termination of the License Agreement (the "Term"). 

        9.2    Termination by BI Pharma.    This Agreement may be terminated with or without cause by
BI Pharma by giving six (6) months prior written notice to ImmunoGen. 

        9.3    Early Termination.    Notwithstanding Section 9.1, either Party may, in addition
to exercising any other available legal or equitable rights or remedies, terminate this Agreement, effective immediately upon the expiration of any applicable cure period, upon the occurrence of an
Event of Default (as defined below) with respect to the other Party. The term "Event of Default" with respect to a Party means the occurrence of any of the following events: 

	(a)
	The
failure of a Party to comply with or perform any material provision of this Agreement, and such failure remains uncured for ninety (90) days following written notice of
such failure (if such default is cured within the cure period, such written notice shall be null and void), provided that, if the defaulting Party can establish to the reasonable satisfaction of the
other Party that it is diligently and actively pursuing a cure at the expiration of the cure period, and that the default is reasonably capable of being cured, then the cure period shall be extended
for so long as a cure is being diligently and actively pursued, not to exceed one hundred and eighty (180) days in the aggregate. 

G-11

 

	(b)
	A
Party (i) becomes unable to pay its debts as they mature, (ii) is the subject of a voluntary or involuntary petition in bankruptcy or of any other proceeding under
bankruptcy, insolvency or similar laws which, if involuntary, is not dismissed within sixty (60) days of the date filed, (iii) makes an assignment for the benefit of creditors,
(iv) is named in, or its property is subject to, a suit for the appointment of a receiver which is not dismissed within sixty (60) days of the date filed, or (v) is dissolved or
liquidated. 

        9.4    Effect of Termination of this Agreement.    The termination of this Agreement shall in
no way affect the validity of the License Agreement. Upon termination, ImmunoGen shall invoice BI Pharma for all costs that are incurred but remain unbilled as of the effective date of termination.
Payment of such invoice shall be pursuant to the terms of Section 7.2 of this Agreement. 

        9.5    Limited Liability.    Except as otherwise provided in this Agreement, neither ImmunoGen
nor BI Pharma will be liable with respect to any subject matter of this Agreement under any contract, negligence, strict liability or other legal or equitable theory for any punitive damages or
indirect, incidental, consequential damages or lost profits, including, without limitation, cost of procurement of substitute goods or technology, or loss of opportunity, loss of income or
compensation for loss of goodwill. 

10.    SECRECY OBLIGATIONS  

        10.1    General Applicability of the Provisions of the License Agreement.    The Parties are
in agreement that the confidentiality and secrecy obligations of the License Agreement shall apply to this Agreement for the Term of this Agreement and for a period of  [ * ] thereafter.

11.    ADDITIONAL OBLIGATIONS OF THE PARTIES  

        11.1    Laws and Regulations.    The Parties agree to comply with all applicable laws, rules,
regulations or requirements in connection with the manufacture of BIWA4, Drug Substance, and Drug Product. 

        11.2    Permits and Licenses for Facility / Regulatory Submissions.    ImmunoGen shall be
responsible for obtaining, at its expense, any Facility or other licenses or permits, and any regulatory and government approvals necessary for the manufacture of Drug Substance and the supply of Drug
Product to BI Pharma in accordance with the terms and conditions of this Agreement. ImmunoGen shall provide to BI Pharma all information relevant to specific methods of Drug Product manufacture and
any other information specific to the Drug Product and relevant to FDA and analogous non-U.S. regulatory submissions, including, without limitation, IND, BLA and other regulatory
submissions, in a timely manner to enable punctual submission by BI Pharma of necessary regulatory documentation. 

        11.3    Notification of Inspections; Communications.    ImmunoGen shall permit BI Pharma or
its agents to be present and participate in any visit to, or inspection of, the Facility as it pertains to Drug Substance or Drug Product or review of the Manufacturing Process by any Competent
Authorities. ImmunoGen shall give prompt notice to BI Pharma of any such visit, inspection or review. ImmunoGen shall promptly provide to BI Pharma all information (including copies of any written
communication) from and to Competent Authorities concerning the Drug Substance or Drug Product, and shall use reasonable commercial efforts to consult with BI Pharma concerning the response of
ImmunoGen to each such communication. It is understood by the Parties that all such communications fall under the confidentiality obligations. 

        11.4    Regulatory Assistance.    ImmunoGen agrees to provide to BI Pharma such information
and assistance relating to the manufacture and quality control of the Drug Product as BI Pharma may reasonably require for purposes of applying for and maintaining all registrations for the Drug
Product 

G-12

 

including, without limitation, providing BI Pharma with all reports, authorizations, certificates, methodologies, and other documentation in the possession or under the control of ImmunoGen relating
to the manufacture and quality control of the Drug Product (or any component thereof). 

        11.5    Debarment.    ImmunoGen represents and warrants that it has not been debarred and is
not subject to a pending debarment and that it will not use in any capacity, in connection with the services to be performed under this Agreement, any person who has been debarred pursuant to
section 306 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 335a, or who is the subject of a conviction described in such section. ImmunoGen agrees to inform BI Pharma in
writing immediately if it or any person who is performing services hereunder is debarred or is the subject of a conviction described in section 306, or if any action, suit, claim,
investigation, or legal or administrative proceeding is pending or, to the best of ImmunoGen's knowledge, is threatened, relating to the debarment or conviction of ImmunoGen or any person performing
services hereunder. 

        11.6    Compliance with U.S. Export Regulations.    BI Pharma understands that Drug Product to
be purchased hereunder may require ImmunoGen to obtain a validated export license from the United States Department of Commerce. It shall be ImmunoGen's task and responsibility to obtain such export
license and BI Pharma agrees to assist ImmunoGen in obtaining any such required license by supplying appropriate documentation reasonably requested by ImmunoGen. In connection therewith, BI Pharma
agrees to comply with U.S. Export Administration Regulations as in effect from time to time and brought to BI Pharma's attention by ImmunoGen. BI Pharma will also maintain all records necessary to
comply with United States Export Administration Regulations brought to BI Pharma's attention by ImmunoGen. 

12.    WARRANTY /LIABILITY  

        12.1.1.    ImmunoGen Representations:    ImmunoGen represents and warrants to BI Pharma that: 

	(a)
	No Conflict. The execution, delivery and performance of this Agreement by ImmunoGen does not conflict with any agreement, instrument or
understanding, oral or written, to which it is a Party or by which it may be bound, and does not violate any law or regulation of any court, governmental body or administrative or other agency having
authority over it. ImmunoGen is not currently a party to, and during the term of this Agreement will not enter into, any agreements, oral or written, that are inconsistent with its obligations under
this Agreement.

	(b)
	Authority. ImmunoGen is validly existing and in good standing under the laws of the state of its incorporation and has the corporate
power and authority to enter into this Agreement. The execution, delivery and performance of this Agreement have been duly authorized by all necessary action on the part of ImmunoGen, its officers and
directors.

	(c)
	Ownership. To ImmunoGen's knowledge, all of the Licensed Patents are subsisting and are valid and enforceable. ImmunoGen (i) has
not previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest in Licensed Patents, or any component of the Licensed Technology, and (ii) has no knowledge
of the existence of any patent, trademark or other intellectual property right (other than any patent application) owned or Controlled by ImmunoGen, other than the Licensed Patent Rights, in case of
either (i) or (ii), that would prevent ImmunoGen and BI Pharma from manufacturing and supplying Drug Product, and BI from exploiting its rights granted under Section 2.1 of the License
Agreement. In addition, ImmunoGen has no knowledge of the existence of any patent or intellectual property right (other than any patent application) owned or 

G-13

 

Controlled
by a third party that would materially conflict with the grant of the license set forth in Section 2.1 of the License Agreement. 

	(d)
	Litigation. There are no claims, judgements or settlements against, pending with respect to the Licensed Patents or any component of
Licensed Technology. In addition, to ImmunoGen's knowledge, no such claims, judgements or settlements are threatened.

	(e)
	Further Warranties: ImmunoGen covenants to BI Pharma that:

	(i)
	The
development and manufacture of Drug Substance and Drug Product by ImmunoGen under this Agreement shall be in compliance with all applicable laws,
requirements and regulations.

	(ii)
	All
Certificates of Analysis which will be provided to BI Pharma under this Agreement shall be generated and documented in accordance with generally
accepted standards of the pharmaceutical industry.

	(iii)
	ImmunoGen
hereby represents and warrants that as of the Effective Date (a) ImmunoGen has entered into the Key Materials Supply Agreements as
listed on Schedule E, and (b) each of the Key Materials Supply Agreements is in full force and effect and constitutes a valid and binding
obligation of ImmunoGen. 

        12.1.2.    BI Pharma Representations and Warranties:    BI Pharma represents, warrants and covenants to ImmunoGen
that: 

	(a)
	No Conflict. The execution, delivery and performance of this Agreement by BI Pharma does not conflict with any agreement, instrument or
understanding, oral or written, to which it is a party or by which it may be bound, and does not violate any law or regulation of any court, governmental body or administrative or other agency having
authority over it. BI Pharma is not currently a party to, and during the term of this Agreement will not enter into, any agreements, oral or written, that are inconsistent with its obligations under
this Agreement.

	(b)
	Authority. BI Pharma is validly existing and in good standing under the laws of the state of its incorporation and has the corporate
power and authority to enter into this Agreement. The execution, delivery and performance of this Agreement have been duly authorized by all necessary action on the part of BI Pharma, its officers and
directors.

	(c)
	BIWA4. BI Pharma's manufacture and delivery of BIWA4 under this Agreement shall be in compliance with the laws, requirements and
regulations applicable thereto in the Territory. 

        12.1.3.    Indemnification by the Parties:    Each party (the "Indemnitor") will indemnify the other party (the
"Indemnitee") against any liability in connection with any claim, suits, liabilities, etc. arising out of the performance by the Indemnitor of its work under this Agreement or the exploitation by the
Indemnitor of its rights under this Agreement, including, without limitation, the development and manufacture of Drug Substance and Drug Product, unless such liability results from (i) the
negligence or wilful misconduct of the Indemnitee or (ii) a breach of the warranties set forth in this Agreement by the Indemnitee. 

        12.1.4.    Indemnification Procedures:    

	(a)
	The
Indemnitee shall: (i) notify the Indemnitor of any liability and full details of the basis therefor with respect to which the Indemnitee intends to claim indemnification as
soon as practicable after the Indemnitee becomes aware of any such liability; (ii) permit the Indemnitor to assume the defence thereof; and (iii) cooperate with the Indemnitor, at the
Indemnitor's expense, in the defence thereof. 

G-14

 

	(b)
	With
respect to any matter for which the Indemnitor has an obligation to indemnify the Indemnitee under this Agreement, the Indemnitee shall have the right to participate and be
represented (at the Indemnitor's expense) by legal counsel of the Indemnitee's choice in all proceedings and negotiations,
if representation by counsel retained by Indemnitor would be inappropriate due to actual or potential differing interests between the Indemnitee and any other party represented by such counsel in such
proceedings.

	(c)
	The
indemnity agreement in this Section 12 shall not apply to amounts paid in settlement of any liability if such settlement is effected without the consent of the Indemnitor,
which consent shall not be unreasonably withheld.

	(d)
	Failure
of the Indemnitee to deliver notice to the Indemnitor within [ * ] after becoming aware
of a liability shall relieve the Indemnitor of any liability to the Indemnitee pursuant to this Section 12 in the event, but only to the extent, such delay is prejudicial to the Indemnitor's
ability to defend such action. 

13.    MISCELLANEOUS  

        13.1    Force Majeure.    The Parties shall not be liable in any respect for failure to
perform their obligations hereunder or for delay in shipment of BIWA4 or Drug Product pursuant to accepted orders where such failure or delay shall have been due wholly or in part to the elements,
acts of God, acts of civil or military authority or terrorism, fires, floods, epidemics, quarantine restrictions, war, riots, strikes, lock outs, break down, differences with workmen, accidents to
machinery, delays in transportation or delays in delivery by suppliers or manufacturers beyond the Parties' control. In event of such force majeure, the Party affected thereby shall use reasonable
efforts to cure or overcome the same and resume performance of its obligations hereunder. 

        13.2    Other Restrictions.    Both Parties will conduct business in a manner that reflects
favorably at all times on the products containing DM1, goodwill, and reputation of the other Party. Without limiting the foregoing, neither Party nor its Affiliates shall engage in any deceptive,
misleading, illegal, unfair, or unethical practices that are or may be detrimental to the other Party or its Affiliates. 

        13.3    Notices.    Unless otherwise and expressly required under this Agreement, all notices
shall be in writing and mailed via certified mail, return receipt requested, courier, or facsimile transmission addressed as follows, or to such other address as may be designated by either Party in
writing to the other Party from time to time: 

	If to ImmunoGen:	 	If to BI Pharma:
	

Attn: Chief Executive Officer

128 Sidney Street

Cambridge, MA 02139

United States of America	
 	

Attn: Clinical Trial Supplies Unit

Department of Pharmaceutical

Research and Development

Birkendorfer Strasse 65

88397 Biberach

Germany

        13.4    Governing Law.    This Agreement shall be governed exclusively by German laws. Where
not as otherwise provided for in this Agreement, in the event of any controversy or claim arising out of or relating to any provision of this Agreement, the Parties shall first try to settle those
conflicts amicably between themselves. Any dispute, controversy or claim initiated by either Party arising out of, resulting from or relating to this Agreement, or the performance by either Party of
its obligations under this Agreement (other than bona fide third Party actions or proceedings filed or instituted in an action or proceeding by a third Party against a Party), whether before or after
termination of this Agreement, shall be finally resolved by binding arbitration. Whenever a Party shall decide to institute arbitration 

G-15

 

proceedings, it shall give written notice to that effect to the other Party. Any such arbitration shall be conducted under the commercial arbitration rules of the ICC by a panel of three arbitrators
appointed in accordance with such rules. Any such arbitration shall be held in [ * ]. The arbitrators shall have the authority to grant specific performance and
to allocate between the Parties the costs of arbitration in such equitable manner as they determine. Judgment upon the award so rendered may be entered in any court having jurisdiction or application
may be made to such court for judicial acceptance of any award and an order of enforcement, as the case may be. In no event shall a demand for arbitration be made after the date when institution of a
legal or equitable proceeding based upon such claim, dispute or other matter in question would be barred by the applicable statute of limitations. Notwithstanding the foregoing, either Party shall
have the right, without waiving any right or remedy available to such Party under this Agreement or otherwise to seek and obtain from any court of jurisdiction any interim or provisional relief that
is necessary or desirable to protect the rights or property of such Party, pending the selection of the arbitrators hereunder or pending the arbitrators' determination of any dispute, controversy or
claim hereunder. 

        13.5    Binding Effect.    This Agreement shall be binding upon and inure to the benefit of
the Parties and their respective legal representatives, successors and permitted assigns. 

        13.6    Headings.    Section and subsection headings are inserted for convenience of reference
only and do not form a part of this Agreement. 

        13.7    Amendment; Waiver.    This Agreement may be amended, modified, superseded or canceled,
and any of the terms may be waived, only by a written instrument executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance. The delay or failure of any Party at any
time or times to require performance of any provisions shall in no manner affect the rights at a later time to enforce the same. No waiver by any Party of any condition or of the breach of any term
contained in this Agreement, whether by conduct, or otherwise, in any one or more instances, shall be deemed to be, or considered as, a further or continuing waiver of any such condition or of the
breach of such term or any other term of this Agreement. 

        13.8    Independent Contractors; No Agency or Partnership.    The relationship between
ImmunoGen and BI Pharma is that of independent contractors. Nothing contained in this Agreement shall give either Party the right to bind the other, or be deemed to constitute the Parties as agents
for the other or as partners with each other or any third party. 

        13.9    Assignment and Successors.    Either Party shall not be entitled to assign or
otherwise transfer its rights and obligations under this Agreement in whole or in part to any third party without the prior written consent of the other Party. 

        13.10    Integration; Severability.    If any provision of this Agreement is or becomes
invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it is the intention of the Parties that the remainder of the Agreement shall not be affected. 

G-16

 

14.    LIST OF SCHEDULES  

	Schedule A:	 	Draft Specifications for Drug Substance and Drug Product as provided by BI Pharma
	

Schedule B:	
 	

Likely List of Dedicated Equipment to define an upper limit of Dedicated Equipment costs, which will be necessary during the production of Drug Product (see Section 5.5)
	

Schedule C:	
 	

Table of Success Rates for Cost Sharing of Failed Batches
	

Schedule D:	
 	

Form of Invoice and Breakdown of Direct Cost
	

Schedule E:	
 	

List of Key Materials Supply Agreements
	

Schedule F:	
 	

Purchase Order BI Pharma
	

Schedule G:	
 	

Provision of Clinical Drug Product
	

Schedule H:	
 	

List of Subcontractors as of Effective Date
	

Schedule I:	
 	

Templates of Certificates of Analysis for Drug Substance and Drug Product

G-17

 

        IN
WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives. 

	 	 	 	 	IMMUNOGEN, INC.
	

 	
 	

 	
 	

By:	
 	

 	
 	

 
	 	 	 	 	 	 	

	 	 	 	 	Title:	 	 	 	 
	 	 	 	 	 	 	

	

 	
 	

 	
 	

BOEHRINGER INGELHEIM PHARMA KG
	

 	
 	

 	
 	

 	
 	

 	
 	

ppa.
	

 	
 	

 	
 	

By:	
 	

 	
 	

 
	 	 	 	 	 	 	

        Authorized
Signatories:    A. Dehio            Dr. H. Michelberger 

G-18

  

 
 

Schedule A
  Draft Specifications    
  

Testing of Drug Substance  

	Test
 
	 	DRAFT specification

	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ](1)
	[ * ]	 	[ * ](1)
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]

	(1)
	This
would depend on the final formulation 

Testing of Drug Product  

	Test
 
	 	DRAFT specification

	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ](1)
	[ * ]	 	[ * ](1)
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]

	(1)
	This
would depend on the final formulation 

A-1

  

 
 

Schedule B    
    
    Likely List of Dedicated Equipment for Clinical BIWI1 Manufacture    
  

ULTRAFILTRATION/DIAFILTRATION  

        1 [ * ] system  [ * ] for ultra- and diafiltration of  [ * ] up to [ * ] (including  [ * ], [ * ],  [ * ] and [ * ])
([ * ]) 

[ * ]

        1
[ * ] system  [ * ] for ultra- and diafiltration of  [ * ] (including
[ * ],  [ * ], [ * ] and  [ * ]
) 

[ * ]

CHROMATOGRAPHY COLUMNS  

        1 [ * ] column  [ * ]

        1
[ * ] column  [ * ]

total
[ * ] for [ * ]

        1
[ * ]
column                                        
                [ * ]
 

        1
[ * ]
column                                        
                [ * ]

        [ * ] include required  [ * ] (e.g. [ * ] and  [ * ]
) and [ * ]. 

B-1

  

 
 

SCHEDULE C    
    
    Cost Sharing for Failed Batches    
  

        Section 6.4 of the Agreement contemplates cost sharing by the Parties for certain Batch Run failures not attributable to either Party. The cost sharing of
such failed batches shall take place in accordance with the table and description below. 

	Successful Batch Runs
 
	 	Success Rate

	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]

Batches [ * ]  

        [ * ] represents the  [ * ] of the [ * ]
 that
result in [ * ] that meets  [ * ] (a [ * ]). The Parties
estimate that for the [ * ], there may be up to  [ * ] that result in [ * ]
that fails to meet [ * ] (a  [ * ]). Therefore, [ * ], in
total, [ * ] up to [ * ] to
achieve the goal of [ * ].  [ * ] shall [ * ] with these  [ * ]. In the event that  [ * ] must [ * ] than
[ * ] to achieve the goal of  [ * ], [ * ] shall  
[ * ] with all [ * ]. 

Batches [ * ]  

        The Parties estimate that for the [ * ] there may be up to three  [ * ]
that result in [ * ]
that [ * ] to meet [ * ].
Therefore, [ * ], in total, conduct up to  [ * ] to achieve the goal of the  [ * ]. [ * ] shall  [ * ] with these [ * ]. In
the event that [ * ] must  [ * ] to achieve the goal of  [ * ], [ * ] shall  [ * ] with [ * ].
 

Batches [ * ]  

        For [ * ] of  [ * ] (e.g. [ * ]
) there may
be up to [ * ]. Therefore,  [ * ], in total, conduct up to  [ * ] to achieve
the goal of  [ * ]. [ * ] shall  [ * ] with these 
[ * ]. In
the event that [ * ] must  [ * ] than [ * ] to achieve
the goal of [ * ], [ * ]
shall [ * ] with [ * ]. 

C-1

 
 

Schedule D    
    
    Form of Invoice and Breakdown of Direct Cost    
  

  

 
 

Schedule E    
    
    List of Key Materials Supply Agreements    
  

	(1)
	For DM1, unpurified ansamitocin P3, and research maytansinol
[ * ] Agreement between  [ * ]
 ([ * ]) and ImmunoGen, Inc.
dated [ * ]Entered
with:
 [ * ]

	(2)
	For ansamitocin P3
[ * ] for the [ * ]of  
[ * ] dated [ * ] and  [ * ]Entered
with:
 [ * ]

E-1

 
 

Schedule F    
    
    Purchase Order BI Pharma    
  

  

 
 

Schedule G    
    
    Provision of Clinical Drug Product    
  

	 
	 	Calendar Year

	 
	 	2002
	 	2003
	 	2004
	 	2005

	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]

G-1

  

 
 

Schedule H    
    
    List of Subcontractors as of Effective Date    
  

[ * ]

[ * ]

H-1

  

 
 

Schedule I    
    
    Template of Certificates of Analysis for Drug Substance and Drug Product    
  

For Drug Substance:  

 
  CERTIFICATE OF ANALYSIS    
  

PRODUCT: 

LOT
NUMBER: 

	TEST
 
	 	RESULT

	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 

This
lot of material was manufactured to [ * ] and to the approved  [ * ]
[[ * ]] 

	QU Approval:	 	 	 	Date:	 	 
	 	 	
	 	 	 	

I-1

 

For Drug Product:  

 
  CERTIFICATE OF ANALYSIS    
  

PRODUCT: 

LOT
NUMBER: 

	TEST
 
	 	RESULT

	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 
	[ * ]	 	 

This
lot of material was manufactured to [ * ] and to the approved  [ * ]
[[ * ]] 

	QU Approval:	 	 	 	Date:	 	 
	 	 	
	 	 	 	

I-2

QuickLinks

Development and License Agreement

Schedule A Licensed Technology

Schedule B Licensed Patent Rights

Schedule C BI Intellectual Property

Schedule D Provision of Non-clinical Drug Substance [g BIWI1]

Schedule E Major Terms of Technical Transfer Plan

Schedule F Development Plan for BIWI1

Plan for the development of Ansamitocin P3 production and DM1 production

Schedule G Clinical Supply Agreement

CLINICAL SUPPLY AGREEMENT

Schedule A Draft Specifications

Schedule B Likely List of Dedicated Equipment for Clinical BIWI1 Manufacture

SCHEDULE C Cost Sharing for Failed Batches

Schedule D Form of Invoice and Breakdown of Direct Cost

Schedule E List of Key Materials Supply Agreements

Schedule F Purchase Order BI Pharma

Schedule G Provision of Clinical Drug Product

Schedule H List of Subcontractors as of Effective Date

Schedule I Template of Certificates of Analysis for Drug Substance and Drug Product

CERTIFICATE OF ANALYSIS

CERTIFICATE OF ANALYSIS<Page>

EXHIBIT 10.21

--------------------------------------------------------------------------------

                             SCHOLASTIC CORPORATION
                         MANAGEMENT STOCK PURCHASE PLAN

--------------------------------------------------------------------------------

                            Effective January 1, 1999

                Amended and Restated Effective December 18, 2002

<Page>

                             SCHOLASTIC CORPORATION
                         MANAGEMENT STOCK PURCHASE PLAN
               (Amended and Restated Effective December 18, 2002)

                                Table Of Contents

<Table>
<S>                                                                             <C>
Article 1 - Introduction........................................................1

Article 2 - Definitions.........................................................1

Article 3 - Shares Reserved.....................................................4

Article 4 - Administration......................................................4

Article 5 - Eligibility.........................................................5

Article 6 - Purchases and Award of RSUs.........................................5

Article 7 - Vesting and Payment of RSUs.........................................6

Article 8 - Dividend Equivalent Amounts.........................................8

Article 9 - Designation of Beneficiary..........................................8

Article 10 - Adjustments........................................................8

Article 11 - Amendment or Termination of Plan...................................9

Article 12 - Miscellaneous Provisions...........................................9
</Table>

                                        i
<Page>

                             SCHOLASTIC CORPORATION
                         MANAGEMENT STOCK PURCHASE PLAN
               (AMENDED AND RESTATED EFFECTIVE DECEMBER 18, 2002)

ARTICLE 1 - INTRODUCTION

       The purpose of the Scholastic Corporation Management Stock Purchase Plan
(the "Plan") is to provide equity incentive compensation to selected management
employees of Scholastic Corporation and its Affiliates. Participants in the Plan
receive restricted stock units ("RSUs") at a discount in lieu of a portion or
all of their bonus awards under the Company's annual incentive plan. Under
certain circumstances, the RSUs convert into shares of Common Stock. The Company
believes that the Plan creates a means to provide deferred compensation to such
selected management employees and to raise the level of stock ownership in the
Company by such employees thereby strengthening the mutuality of interests
between such employees and the Company's stockholders.

ARTICLE 2 - DEFINITIONS

2.1    AFFILIATE - (i) any corporation, partnership, limited liability company
       or other entity as to which the Company possesses a direct or indirect
       ownership interest of at least fifty (50) percent or which possesses a
       direct or indirect ownership interest of at least 50% in the Company
       including, without limitation, any subsidiary corporation (as defined in
       Section 424(f) of the Code) and parent corporation (as defined in Section
       424(e) of the Code) and (ii) any other entity in which the Company or any
       of its Affiliates has a material equity interest, as determined by the
       Committee.

2.2    AWARD DATE - the first business day after the end of the fiscal quarter
       in which a Bonus for a year is paid or otherwise would have been paid.

2.3    AWARD VALUE - the Fair Market Value of a share of Common Stock on the
       Award Date.

2.4    BENEFICIARY - a Beneficiary or Beneficiaries designated by the
       Participant under Article 9.

2.5    BONUS - a Participant's annual award for a Fiscal Year under any annual
       incentive plan of the Company or its Affiliates that has been designated
       by the Committee as eligible for deferral under the Plan pursuant to a
       Subscription Agreement.

2.6    BOARD OF DIRECTORS - the Board of Directors of the Company or the
       Executive Committee of such Board of Directors.

2.7    CAUSE - any of the following: (i) any act or acts by the Participant
       constituting a felony under the laws of the United States, any state
       thereof, or any political subdivision thereof, (ii) the Participant's
       willful and continued failure to perform the duties assigned to him or
       her as an employee of the Company or Affiliate; (iii) any material breach
       by the

<Page>

       Participant of any employment agreement with the Company or Affiliate;
       (iv) dishonesty, gross negligence or malfeasance by the Participant in
       the performance of his or her duties as an employee of the Company or any
       Affiliate or any conduct by the Participant which involves a material
       conflict of interest with any business of the Company or its Affiliates;
       or (v) taking or knowingly omitting to take any other action or actions
       in the performance of the Participant's duties as an employee of the
       Company or its Affiliates without informing appropriate members of
       management to whom such Participant reports, which in the determination
       of the Committee have caused or substantially contributed to the material
       deterioration in the business of the Company and its Affiliates, taken as
       a whole.

2.8    CODE - the Internal Revenue Code of 1986, as amended from time to time.

2.9    COMMITTEE - the committee of the Board of Directors authorized to
       administer the Plan. To the extent that no Committee exists which has the
       authority to administer the Plan, the functions of the Committee shall be
       exercised by the Board of Directors. The Committee shall consist of two
       or more non-employee directors, each of whom is intended to be, to the
       extent required by Rule 16b-3, a "non-employee director" as defined in
       Rule 16b-3. If for any reason the appointed Committee does not meet the
       requirements of Rule 16b-3, such noncompliance shall not affect the
       validity of any grants of RSUs hereunder, interpretations or other
       actions of the Committee.

2.10   COMMON STOCK OR STOCK - common stock of the Company, par value $.01 per
       share.

2.11   COMPANY - Scholastic Corporation, a corporation organized under the laws
       of the State of Delaware (or any successor).

2.12   COST - the cost of purchasing an RSU under the Plan as of an Award Date,
       as determined by the Committee in its sole discretion, but in no event
       less than seventy-five (75%) percent of the lowest Fair Market Value of a
       share of Common Stock during the fiscal quarter immediately preceding the
       Award Date. The cost shall be established as of the applicable Award Date
       and shall remain in effect unless modified by the Committee at least
       thirty (30) days prior to the applicable Award Date.

2.13   DEFERRAL PERIOD - a period of time (expressed in whole years) not less
       than three years beginning on an Award Date as specified by the
       Participant in his or her Subscription Agreement (as may be modified by
       the Participant from time to time in accordance with procedures
       established by or on behalf of the Committee) with respect to RSUs
       awarded on that Award Date; provided, however, that the Committee may
       establish, in its sole discretion, a fixed date as the end of the
       Deferral Period or fixed period specified with respect to RSUs awarded on
       that Award Date.

2.14   DISABILITY - complete and permanent inability by reason of illness or
       accident to perform the duties of the occupation at which the Participant
       was employed when such disability commenced, as determined by the
       Committee based on medical evidence available to it.

                                        2
<Page>

2.15   EXCHANGE ACT - the Securities Exchange Act of 1934, as amended.

2.16   FAIR MARKET VALUE - unless otherwise required by any applicable provision
       of the Code or any regulations issued thereunder, as of any date, the
       last sales price reported for the Common Stock on the applicable date:
       (i) as reported on the principal national securities exchange on which it
       is then traded or the NASDAQ Stock Market, Inc. or (ii) if not traded on
       any such national securities exchange or the NASDAQ Stock Market, Inc. as
       quoted on an automated quotation system sponsored by the National
       Association of Securities Dealers, Inc. If the Common Stock is not
       readily tradable on a national securities exchange, the NASDAQ Stock
       Market, Inc. or any automated quotation system sponsored by the National
       Association of Securities Dealers, Inc., its Fair Market Value shall be
       set in good faith by the Committee.

2.17   FISCAL YEAR - the fiscal year of the Company.

2.18   FOREIGN JURISDICTION - any jurisdiction outside of the United States
       including, without limitation, countries, states, provinces and
       localities.

2.19   PARTICIPANT - a management employee of the Company or any Affiliate who
       satisfies the eligibility requirements under Article 5 of the Plan and
       elects to participate in the Plan in accordance with its terms.

2.20   PLAN - the Scholastic Corporation Management Stock Purchase Plan, as
       amended from time to time.

2.21   PLAN YEAR - the Fiscal Year, except that the first Plan Year shall be the
       short year beginning on the effective date of the Plan and ending on May
       31, 1999.

2.22   RETIREMENT - termination of employment with the Company and all
       Affiliates on or after age fifty-five (55); provided that, with respect
       to any Deferral Period commencing on or after January 1, 2003,
       "Retirement" shall mean a termination of employment with the Company and
       all Affiliates on or after age fifty-five (55) in accordance with the
       Company's standard retirement policies.

2.23   RULE 16b-3 - means Rule 16b-3 promulgated under Section 16(b) of the
       Exchange Act or any successor provision.

2.24   RSU - a unit of measurement equivalent to one share of Common Stock but
       with none of the attendant rights of a stockholder of a share of Common
       Stock, including the right to vote (if any); except that an RSU shall
       have the dividend right described in Article 8. The fair market value of
       an RSU on any date shall be deemed to be the Fair Market Value of a share
       of Common Stock on that date.

2.25   SUBSCRIPTION AGREEMENT - an agreement executed by a Participant setting
       forth his or her election to defer receipt of a portion or all of his or
       her Bonus for the Deferral Period and

                                        3
<Page>

       to authorize the Company to credit such amount to the Plan in order to
       purchase an award of RSU. A Subscription Agreement shall contain such
       provisions, consistent with the provisions of the Plan, as may be
       established from time to time by the Company or Committee.
       Notwithstanding the foregoing, a Participant may amend a Subscription
       Agreement to extend a Deferral Period, in such manner prescribed by or on
       behalf of the Committee; provided that no such amendment shall be
       effective unless made at least (i) one (1) year prior to his or her
       termination of employment or (ii) one (1) year prior to the end of the
       Deferral Period specified in a current Subscription Agreement.

ARTICLE 3 - SHARES RESERVED

       The aggregate number of shares of Common Stock reserved for issuance
pursuant to the Plan or with respect to which RSUs may be granted shall be
150,000, subject to adjustment as provided in Article 10 hereof.

       Such number of shares may be set aside out of the authorized but unissued
shares of Common Stock not reserved for any other purpose, or out of issued
shares of Common Stock acquired for and held in the treasury of the Company. If
any RSU awarded under the Plan is forfeited, terminated or canceled for any
reason, the share of Common Stock relating to such RSU shall again be available
under the Plan. If Common Stock has been exchanged by a Participant as full or
partial payment to the Company for withholding taxes or otherwise or if the
number of shares of Common Stock otherwise deliverable has been reduced for
withholding, the number of shares exchanged or reduced shall again be available
under the Plan.

ARTICLE 4 - ADMINISTRATION

4.1    The Plan shall be administered by the Committee. The Committee may select
       an administrator or any other person to whom its duties and
       responsibilities hereunder may be delegated. The Committee shall have
       full power and authority, subject to the provisions of the Plan, to
       promulgate such rules and regulations as it deems necessary for the
       proper administration of the Plan, to interpret the provisions and
       supervise the administration of the Plan, and to take all actions in
       connection therewith or in relation thereto as it deems necessary or
       advisable. The Committee may adopt special guidelines and provisions for
       persons who are residing in, or subject to the laws of, Foreign
       Jurisdictions to comply with applicable tax and securities laws. All
       interpretations and determinations of the Committee shall be made in its
       sole and absolute discretion based on the Plan document and shall be
       final, conclusive and binding on all parties with respect to all matters
       relating to the Plan.

4.2    The Committee may employ such legal counsel, consultants, brokers and
       agents as it may deem desirable for the administration of the Plan and
       may rely upon any opinion received from any such counsel or consultant
       and any computation received from any such consultant, broker or agent.
       The Committee may, in its sole discretion, designate an agent to
       administer the Plan, keep records, send statements of account to
       Participants and to perform other duties relating to the Plan, as the
       Committee may request from time to

                                        4
<Page>

       time. The Committee may adopt, amend or repeal any guidelines or
       requirements necessary for the delivery of the Common Stock.

4.3    The Company shall, to the fullest extent permitted by law and the
       Certificate of Incorporation and By-laws of the Company, to the extent
       not covered by insurance, indemnify each director, officer or employee of
       the Company and its Affiliates (including the respective heirs,
       executors, administrators and other personal representatives of such
       persons) and each member of the Committee against all expenses, costs,
       liabilities and losses (including attorneys' fees, judgments, fines,
       excise taxes or penalties, and amounts paid or to be paid in settlement)
       actually and reasonably incurred by such person in connection with any
       threatened, pending or actual suit, action or proceeding (whether civil,
       criminal, administrative or investigative in nature or otherwise) in
       which such person may be involved by reason of the fact that he or she is
       or was serving this Plan in any capacity at the request of the Company,
       except in instances where any such person engages in willful neglect or
       fraud. Such right of indemnification shall include the right to be paid
       by the Company for expenses incurred or reasonably anticipated to be
       incurred in defending any such suit, action or proceeding in advance of
       its disposition; provided, however, that the payment of expenses in
       advance of the settlement or final disposition of a suit, action or
       proceeding shall be made only upon delivery to the Company of an
       undertaking by or on behalf of such person to repay all amounts so
       advanced if it is ultimately determined that such person is not entitled
       to be indemnified hereunder. Such indemnification shall be in addition to
       any rights of indemnification the person may have as a director, officer
       or employee or under the Certificate of Incorporation of the Company or
       the By-Laws of the Company. Expenses incurred by the Committee or the
       Board in the engagement of any such counsel, consultant or agent shall be
       paid by the Company.

ARTICLE 5 - ELIGIBILITY

       Management employees of the Company and its Affiliates as designated by
the Committee shall be eligible to participate in the Plan. Eligibility for
participation in the Plan shall be determined by the Committee in its sole
discretion. The Committee may, in its sole discretion, designate, on a
prospective basis, any Participant in the Plan as ineligible to receive awards
of RSUs pursuant to Article 6 of the Plan.

ARTICLE 6 - PURCHASES

6.1    GENERAL.
       Each Participant shall be entitled to elect to receive up to one hundred
       (100%) percent of his or her Bonus as an award of RSU. As of the
       applicable Award Date, RSUs shall be awarded to Participants and credited
       to accounts held under the Plan on behalf of Participants on a book-entry
       basis calculated in the manner provided under Section 6.3.

6.2    VOLUNTARY PURCHASES.
       No later than the last day of the first quarter of each Fiscal Year, each
       Participant may elect to receive up to one hundred (100%) percent of his
       or her Bonus for that Fiscal Year

                                        5
<Page>

       as an award of RSUs by completing a Subscription Agreement.
       Notwithstanding the foregoing, for the first Plan Year of any
       Participant, a Participant may elect to participate in the Plan for that
       Plan Year no later than the date set by the Committee in its sole
       discretion pursuant to procedures set by the Committee. If an employee of
       the Company or an Affiliate first becomes eligible to participate
       hereunder during a Plan Year, such employee may elect to participate in
       the Plan for that Plan Year pursuant to procedures established by the
       Committee (solely with respect to the PRO RATA portion of the Bonus
       earned after the Subscription Agreement is executed and delivered to the
       Company). The Subscription Agreement shall provide that the Participant
       elects to receive RSUs in lieu of a specified portion of his or her
       Bonus. Such portion may be expressed as:

       (a)   a specified percentage of up to one hundred (100%) percent (in
             whole percentages) of the Participant's actual Bonus amount;

       (b)   a specified dollar amount, up to one hundred (100%) percent of the
             Participant's actual Bonus amount; or

       (c)   the lesser of the amount specified in Section 6.2(a) or (b).

             Amounts specified pursuant to any of the methods set forth herein
       are entirely contingent on, and are limited to, the cash amount of Bonus
       actually awarded. Each Subscription Agreement, in addition, shall specify
       a Deferral Period with respect to the RSUs to which it pertains. The
       Committee may, in its sole discretion, permit the Deferral Period with
       respect to the RSUs to which it pertains to be changed upon one year's
       notice to the Committee. Other than with respect to the first Plan Year
       or with respect to an employee of the Company or an Affiliate who first
       becomes eligible to participate hereunder during a Plan Year,
       Subscription Agreements must be received by the Company no later than the
       last day of the first quarter of the Fiscal Year for which such Bonus
       amount will be determined. With respect to any Plan Year, an election to
       receive RSUs in lieu of a portion or all of a Bonus hereunder pursuant to
       a Subscription Agreement is irrevocable on and after the date the
       Subscription Agreement must be submitted to the Company and is valid
       solely for the Plan Year to which the election relates. If no new
       Subscription Agreement is timely made with respect to any subsequent Plan
       Year, the Bonus earned in such Plan Year shall not be deferred under the
       Plan.

6.3    AWARDS OF RSUs.
       The Company shall award RSUs to each Participant's account under the Plan
       on the Award Date. Each Participant's account shall be credited with a
       number of RSUs (in whole and fractional RSUs) determined by dividing (a)
       the amount of the Participant's Bonus to be received as an award of RSUs
       in accordance with the Participant's Subscription Agreement and the
       methodology under Section 6.2 by (b) the Cost of an RSU on the Award
       Date.

                                        6
<Page>

ARTICLE 7 - VESTING AND PAYMENT OF RSUs

7.1    VESTING.
       A Participant shall be fully vested in each RSU three years after the
       Award Date pertaining to that RSU (provided that the Participant is
       continuously employed (including any period during which the Participant
       is on a leave of absence, either paid or unpaid, which is approved by the
       Committee, or any other break in employment which is approved by the
       Committee) by the Company or any Affiliate for such years) or, if
       earlier, upon death while employed, Disability while employed or
       Retirement. The Committee may, in its sole discretion, accelerate (in
       whole or part) the time at which any such RSUs may be vested, based on
       such factors, if any, as the Committee shall determine in its sole
       discretion.

7.2    PAYMENT ON OR AFTER VESTING.
       With respect to each vested RSU, the Company shall issue to the
       Participant one share of Common Stock and cash in lieu of any fractional
       RSU as soon as practicable after the end of the Deferral Period specified
       in the Participant's Subscription Agreement pertaining to such RSU, or,
       if earlier, the Participant's termination of employment with the Company
       and its Affiliates or the termination of the Plan.

7.3    PAYMENT PRIOR TO VESTING.

       (a)   VOLUNTARY TERMINATION; TERMINATION FOR CAUSE. If a Participant
             voluntarily terminates his or her employment with the Company and
             its Affiliates for reasons other than death or Disability or is
             involuntarily terminated by the Company or an Affiliate for Cause,
             the Participant's nonvested RSUs shall be canceled, and he or she
             shall receive as soon as practicable after his or her termination
             of employment with the Company and its Affiliates a cash payment
             equal to the lesser of:

                    i)   an amount equal to the number of those nonvested RSUs
                         awarded on each Award Date multiplied by the respective
                         Cost of those RSUs; or

                    ii)  an amount equal to the number of those nonvested RSUs
                         awarded on each Award Date multiplied by the Fair
                         Market Value of a share of Common Stock on the date of
                         the Participant's termination of employment with the
                         Company and its Affiliates.

       (b)   INVOLUNTARY TERMINATION. If a Participant's employment is
             terminated by the Company and its Affiliates for any reason other
             than Cause, the Participant's nonvested RSUs shall be canceled and
             he or she shall receive payment as soon as practicable following
             his or her termination of employment with the Company and its
             Affiliates as described below:

                                        7
<Page>

                    i)   The number of nonvested RSUs awarded on each Award Date
                         shall be multiplied by a fraction, the numerator of
                         which is the number of full years that the Participant
                         was employed by the Company and its Affiliates after
                         that Award Date and the denominator of which is three;
                         and the Participant shall receive the resulting number
                         of such whole RSUs in shares of Common Stock, with any
                         fractional RSU paid in cash.

                    ii)  With respect to the Participant's remaining nonvested
                         RSUs, the Participant shall receive cash in an amount
                         equal to the lesser of: (A) the number of such
                         nonvested RSUs awarded on each Award Date multiplied by
                         the respective Cost of those RSUs; or (B) the number of
                         those nonvested RSUs awarded on each Award Date
                         multiplied by the Fair Market Value of a share of
                         Common Stock on the date of the Participant's
                         termination of employment with the Company and its
                         Affiliates.

       (c)   COMMITTEE'S DISCRETION. The Committee shall have complete
             discretion to determine the circumstances of a Participant's
             termination of employment with the Company and its Affiliates,
             including whether the same results from voluntary termination,
             Disability, Retirement, death or termination by the Company for or
             not for Cause, and the Committee's determination shall be final and
             binding on all parties and not subject to review or challenge by
             any Participant or other person.

ARTICLE 8 - DIVIDEND EQUIVALENT AMOUNTS

       Whenever dividends (other than dividends payable only in shares of Common
Stock) are paid with respect to shares of Common Stock, each Participant shall
be paid an amount in cash equal to the number of his or her vested RSUs
multiplied by the dividend value per share. Dividends (other than dividends
payable only in shares of Common Stock) shall not be credited or paid with
respect to each Participant's nonvested RSUs.

ARTICLE 9 - DESIGNATION OF BENEFICIARY

       A Participant may designate one or more Beneficiaries to receive payments
or shares of Common Stock in the event of his or her death. A designation of
Beneficiary shall apply to a specified percentage of a Participant's entire
interest in the Plan. Such designation, or any change therein, must be in
writing in a form acceptable to the Company and shall be effective upon receipt
by the Company. If there is no effective designation of Beneficiary, or if no
Beneficiary survives the Participant, the Participant's estate shall be deemed
to be the Beneficiary.

                                        8
<Page>

ARTICLE 10 - ADJUSTMENTS

       In the event of a stock dividend, stock split, reverse stock split,
combination or reclassification of shares, recapitalization, merger,
consolidation, exchange, spin-off or other event which affects Common Stock, the
Committee shall make appropriate equitable adjustments in:

       (a)   the number or kind of shares of Common Stock or securities with
             respect to which RSUs shall thereafter be granted;

       (b)   the number and kind of shares of Common Stock remaining subject to
             outstanding RSUs;

       (c)   the number of RSUs credited to each Participant; and

       (d)   the method of determining the value of RSUs.

ARTICLE 11 - AMENDMENT OR TERMINATION OF PLAN

       The Company reserves the right to amend, terminate or freeze the Plan at
any time, by action of its Board of Directors (or a duly authorized committee
thereof ) or the Committee, provided that no such action shall adversely affect
a Participant's rights under the Plan with respect to RSUs awarded and vested
before the date of such action. No amendment shall be effective unless approved
by the stockholders of the Company if stockholder approval of such amendment is
required to comply with any applicable law, regulation or stock exchange rule.
Upon termination of the Plan, any vested RSU shall be paid in accordance with
Section 7.2 of the Plan and any nonvested RSU shall be canceled and paid in
accordance with Section 7.3(b) of the Plan except that such amount shall be paid
as soon as administratively practicable following the Plan termination. Upon
freezing of the Plan, all vested RSUs shall continue to be held under the Plan
until the Deferral Period expires and all nonvested RSUs shall vest or become
canceled in accordance with the terms of the Plan.

ARTICLE 12 - MISCELLANEOUS PROVISIONS

12.1   NO DISTRIBUTION; COMPLIANCE WITH LEGAL REQUIREMENTS.
       The Committee may require each person acquiring shares of Common Stock
       under the Plan to represent to and agree with the Company in writing that
       such person is acquiring the shares without a view to distribution
       thereof. No shares of Common Stock shall be issued until all applicable
       securities law and other legal and stock exchange requirements have been
       satisfied. The Committee may require the placing of such stop-orders and
       restrictive legends on certificates for Common Stock as it deems
       appropriate.

12.2   WITHHOLDING.
       Participation in the Plan is subject to any required tax withholding on
       wages or other income of the Participant in connection with the Plan.
       Each Participant agrees, by

                                        9
<Page>

       entering the Plan, that the Company or the Affiliate employing the
       Participant shall have the right to deduct any federal, state or local
       income taxes or other taxes, in its sole discretion, from any amount
       payable to the Participant under the Plan or from any payment of any kind
       otherwise due to the Participant. Upon the vesting of the RSU, prior to
       the issuance or delivery of shares of Common Stock or the payment of any
       cash hereunder, a Participant shall pay all required withholding to the
       Company and, if applicable, an Affiliate. Without limiting the generality
       of the foregoing, any withholding obligation with regard to any
       Participant may be satisfied by: (i) reducing the number of shares of
       Common Stock otherwise deliverable to the Participant; (ii) subject to
       the Committee's prior consent, any method approved by the Committee which
       may include the Participant delivering shares of Common Stock already
       owned for at least six months (or such other period to avoid an
       accounting charge against the Company's earnings) and held free and clear
       of all encumbrances to the Company; or (iii) by the Participant paying
       cash directly to the Company.

12.3   NOTICES; DELIVERY OF STOCK CERTIFICATES.
       Any notice required or permitted to be given by the Company or the
       Committee pursuant to the Plan shall be deemed given when personally
       delivered or deposited in the United States mail, registered or
       certified, postage prepaid, addressed to the Participant at the last
       address shown for the Participant on the records of the Company. Delivery
       of stock certificates to persons entitled to receive them under the Plan
       shall be deemed effected for all purposes when the Company or a share
       transfer agent of the Company shall have deposited such certificates in
       the United States mail, addressed to such person at his/her last known
       address on file with the Company.

12.4   NONTRANSFERABILITY OF RIGHTS
       During a Participant's lifetime, no payment or issuance of shares under
       the Plan shall be made to anyone except the Participant otherwise than by
       will or the laws of descent and distribution. No RSU or other interest
       under the Plan shall be subject in any manner to anticipation,
       alienation, sale, transfer, assignment, pledge, encumbrance, garnishment,
       execution, levy or charge, and any attempt by a Participant or any
       Beneficiary under the Plan to do so shall be void. No interest under the
       Plan shall in any manner be liable for or subject to the debts,
       contracts, liabilities, engagements or torts or a Participant or
       Beneficiary entitled thereto.

12.5   OBLIGATIONS UNFUNDED AND UNSECURED.
       The Plan shall at all times be entirely unfunded, and no provision shall
       at any time be made with respect to segregating assets of the Company
       (including Common Stock) for payment of any amounts or issuance of any
       shares of Common Stock hereunder. No Participant or other person shall
       own any interest in any particular assets of the Company or any Affiliate
       (including Common Stock) by reason of the right to receive payment under
       the Plan, and any Participant or other person shall have only the rights
       of a general unsecured creditor of the Company with respect to any rights
       under the Plan. Nothing contained in this Plan and no action taken
       pursuant to the provisions of this Plan shall create or be construed to
       create a trust of any kind, or a fiduciary relationship amongst the

                                       10
<Page>

       Company, any Affiliate, the Committee, and the Participants, their
       designated Beneficiaries or any other person. Any funds which may be
       invested under the provisions of this Plan shall continue for all
       purposes to be part of the general funds of the Company and no person
       other than the Company shall by virtue of the provisions of this Plan
       have any interest in such funds. If the Company decides to establish any
       accrued reserve on its books against the future expense of benefits
       payable hereunder, or if the Company establishes a rabbi trust under this
       Plan, such reserve or trust shall not under any circumstances be deemed
       to be an asset of the Plan.

12.6   GOVERNING LAW.
       The Plan is established in order to provide deferred compensation to a
       select group of management and highly compensated employees within the
       meanings of Sections 201(2) and 301(a)(3) of the Employee Retirement
       Income Security Act of 1974, as amended ("ERISA"). To the extent legally
       required, the Code and ERISA shall govern the Plan and, if any provision
       hereof is in violation of any applicable requirement thereof, the Company
       reserves the right to retroactively amend the Plan to comply therewith.
       To the extent not governed by the Code and ERISA, the terms of the Plan
       shall be governed, construed, administered and regulated in accordance
       with the laws of Delaware. In the event any provision of this Plan shall
       be determined to be illegal or invalid for any reason, the other
       provisions shall continue in full force and effect as if such illegal or
       invalid provision had never been included herein.

12.7   CLAIMS PROCEDURE
       A Participant or Beneficiary shall make any claim (and, in the case of
       the denial of such claim, any appeal) in writing to the Committee or such
       other person designated by the Committee in accordance with the claims
       procedure established by the Committee, which is intended to comply with
       the claims procedure provided under ERISA and U.S. Department of Labor
       Regulation Section 2560.503- 1.

12.8   RULE 16B-3
       To the extent required, the Plan is intended to comply with Rule 16b-3
       and the Committee shall interpret and administer the provisions of the
       Plan in a manner consistent therewith. If a management employee is
       designated by the Committee to participate hereunder, any election to
       receive an award of RSUs shall be deemed approved by such Committee and
       shall be deemed an exempt purchase under Rule 16b-3. Any provisions
       inconsistent with Rule 16b-3 shall be inoperative and shall not affect
       the validity of the Plan.

12.9   NO EMPLOYMENT RIGHTS.
       The establishment and operation of this Plan shall not confer any legal
       rights upon any Participant or other person for a continuation of
       employment, nor shall it interfere with the rights of the Company or
       Affiliate to discharge any employee and to treat him or her without
       regard to the effect which that treatment might have upon him or her as a
       Participant or potential Participant under the Plan.

                                       11
<Page>

12.10  SEVERABILITY OF PROVISIONS.
       If any provision of the Plan shall be held invalid or unenforceable, such
       invalidity or unenforceability shall not affect any other provisions
       hereof, and the Plan shall be construed and enforced as if such
       provisions had not been included.

12.11  CONSTRUCTION.
       The use of a masculine pronoun shall include the feminine, and the
       singular form shall include the plural form, unless the context clearly
       indicates otherwise. The headings and captions herein are provided for
       reference and convenience only, shall not be considered part of the Plan,
       and shall not be employed in the construction of the Plan.

12.12  EFFECTIVE DATE OF PLAN.
       The Plan is adopted, effective upon January 1, 1999, subject to approval
       of the stockholders of the Company as provided under applicable law,
       regulation or stock exchange rule.

                                       12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00046-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00046-of-00352.parquet"}]]